Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7094506,half-life,"Mean plasma pentobarbital half-life was 24 +/- 10 (mean +/- SD) hr in the SLE patients, which is only slightly shorter than the 26 +/- 12 hr in the control subjects.",Microsomal hydroxylation as measured by pentobarbital elimination in patients with idiopathic systemic lupus erythematosus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094506/),h,24,3158,DB00312,Pentobarbital
,7094506,half-life,"Mean plasma pentobarbital half-life was 24 +/- 10 (mean +/- SD) hr in the SLE patients, which is only slightly shorter than the 26 +/- 12 hr in the control subjects.",Microsomal hydroxylation as measured by pentobarbital elimination in patients with idiopathic systemic lupus erythematosus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094506/),h,26,3159,DB00312,Pentobarbital
,7094506,apparent volume of distribution,"The mean apparent volume of distribution in the patients was 1.28 +/- 0.30 l/kg, which is slightly above the 1.00 +/- 0.37 l/kg in the normal subject (P less than 0.05).",Microsomal hydroxylation as measured by pentobarbital elimination in patients with idiopathic systemic lupus erythematosus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094506/),[l] / [kg],1.28,3160,DB00312,Pentobarbital
,7094506,apparent volume of distribution,"The mean apparent volume of distribution in the patients was 1.28 +/- 0.30 l/kg, which is slightly above the 1.00 +/- 0.37 l/kg in the normal subject (P less than 0.05).",Microsomal hydroxylation as measured by pentobarbital elimination in patients with idiopathic systemic lupus erythematosus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094506/),[l] / [kg],1.00,3161,DB00312,Pentobarbital
,7094506,metabolic clearance rate,"Mean metabolic clearance rate in the SLE patients was 0.045 +/- 0.022 l/hr/kg, which is more than the 0.028 +/- 0.008 l/hr/kg in the normal control subjects (P less than 0.02).",Microsomal hydroxylation as measured by pentobarbital elimination in patients with idiopathic systemic lupus erythematosus. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094506/),[l] / [h·kg],0.045,3162,DB00312,Pentobarbital
,7094506,metabolic clearance rate,"Mean metabolic clearance rate in the SLE patients was 0.045 +/- 0.022 l/hr/kg, which is more than the 0.028 +/- 0.008 l/hr/kg in the normal control subjects (P less than 0.02).",Microsomal hydroxylation as measured by pentobarbital elimination in patients with idiopathic systemic lupus erythematosus. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094506/),[l] / [h·kg],0.028,3163,DB00312,Pentobarbital
,19770671,heart rate,"In conscious and anesthetized dogs, torcetrapib increased mean arterial pressure 25 and 18 mm Hg and heart rate 35 and 21 beats/min, at 2.94 and 3.99 microg/mL, respectively.",Cardiovascular effects of torcetrapib in conscious and pentobarbital-anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19770671/),[beats] / [min],35,19598,DB00312,Pentobarbital
,19770671,heart rate,"In conscious and anesthetized dogs, torcetrapib increased mean arterial pressure 25 and 18 mm Hg and heart rate 35 and 21 beats/min, at 2.94 and 3.99 microg/mL, respectively.",Cardiovascular effects of torcetrapib in conscious and pentobarbital-anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19770671/),[beats] / [min],21,19599,DB00312,Pentobarbital
,2047596,elimination half-life,"A significant increase in elimination half-life (around 180 per cent), volume of distribution (130 per cent) and mean residence time (154 to 170 per cent) was observed in sheep infected by the parasite for four to 12 weeks.",Pharmacokinetics of ampicillin and pentobarbital in the course of subclinical fascioliasis in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2047596/),%,180,25340,DB00312,Pentobarbital
,2047596,volume of distribution,"A significant increase in elimination half-life (around 180 per cent), volume of distribution (130 per cent) and mean residence time (154 to 170 per cent) was observed in sheep infected by the parasite for four to 12 weeks.",Pharmacokinetics of ampicillin and pentobarbital in the course of subclinical fascioliasis in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2047596/),%,130,25341,DB00312,Pentobarbital
,2047596,mean residence time,"A significant increase in elimination half-life (around 180 per cent), volume of distribution (130 per cent) and mean residence time (154 to 170 per cent) was observed in sheep infected by the parasite for four to 12 weeks.",Pharmacokinetics of ampicillin and pentobarbital in the course of subclinical fascioliasis in sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2047596/),%,154 to 170,25342,DB00312,Pentobarbital
,11522052,detection limit,The UV detector wavelength was set at 205 nm and the detection limit of ropivacaine was 20 ng/ml.,Simultaneous determination of unbound ropivacaine in rat blood and brain using microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11522052/),[ng] / [ml],20,32603,DB00312,Pentobarbital
,8896200,Ka,"The pharmacokinetic parameters showed a fast absorption rate (Ka = 0.058 min-1), a fast and high distribution of venom to tissues (t1/2 alpha = 31.50 min and Vdarea = 6800.47 ml.kg-1, respectively), a great affinity of the venom for the tissues (KCT = 0.056 min-1 and KTC = 0.002 min-1) and a slow elimination half-life (t1/2 beta = 173.25 min).",Pharmacokinetics of Tityus serrulatus scorpion venom determined by enzyme-linked immunosorbent assay in the rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896200/),1/[min],0.058,39521,DB00312,Pentobarbital
,8896200,t1/2 alpha,"The pharmacokinetic parameters showed a fast absorption rate (Ka = 0.058 min-1), a fast and high distribution of venom to tissues (t1/2 alpha = 31.50 min and Vdarea = 6800.47 ml.kg-1, respectively), a great affinity of the venom for the tissues (KCT = 0.056 min-1 and KTC = 0.002 min-1) and a slow elimination half-life (t1/2 beta = 173.25 min).",Pharmacokinetics of Tityus serrulatus scorpion venom determined by enzyme-linked immunosorbent assay in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896200/),min,31.50,39522,DB00312,Pentobarbital
,8896200,Vdarea,"The pharmacokinetic parameters showed a fast absorption rate (Ka = 0.058 min-1), a fast and high distribution of venom to tissues (t1/2 alpha = 31.50 min and Vdarea = 6800.47 ml.kg-1, respectively), a great affinity of the venom for the tissues (KCT = 0.056 min-1 and KTC = 0.002 min-1) and a slow elimination half-life (t1/2 beta = 173.25 min).",Pharmacokinetics of Tityus serrulatus scorpion venom determined by enzyme-linked immunosorbent assay in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896200/),[ml] / [kg],6800.47,39523,DB00312,Pentobarbital
,8896200,KCT,"The pharmacokinetic parameters showed a fast absorption rate (Ka = 0.058 min-1), a fast and high distribution of venom to tissues (t1/2 alpha = 31.50 min and Vdarea = 6800.47 ml.kg-1, respectively), a great affinity of the venom for the tissues (KCT = 0.056 min-1 and KTC = 0.002 min-1) and a slow elimination half-life (t1/2 beta = 173.25 min).",Pharmacokinetics of Tityus serrulatus scorpion venom determined by enzyme-linked immunosorbent assay in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896200/),1/[min],0.056,39524,DB00312,Pentobarbital
,8896200,KTC,"The pharmacokinetic parameters showed a fast absorption rate (Ka = 0.058 min-1), a fast and high distribution of venom to tissues (t1/2 alpha = 31.50 min and Vdarea = 6800.47 ml.kg-1, respectively), a great affinity of the venom for the tissues (KCT = 0.056 min-1 and KTC = 0.002 min-1) and a slow elimination half-life (t1/2 beta = 173.25 min).",Pharmacokinetics of Tityus serrulatus scorpion venom determined by enzyme-linked immunosorbent assay in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896200/),1/[min],0.002,39525,DB00312,Pentobarbital
,8896200,elimination half-life (t1/2 beta,"The pharmacokinetic parameters showed a fast absorption rate (Ka = 0.058 min-1), a fast and high distribution of venom to tissues (t1/2 alpha = 31.50 min and Vdarea = 6800.47 ml.kg-1, respectively), a great affinity of the venom for the tissues (KCT = 0.056 min-1 and KTC = 0.002 min-1) and a slow elimination half-life (t1/2 beta = 173.25 min).",Pharmacokinetics of Tityus serrulatus scorpion venom determined by enzyme-linked immunosorbent assay in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896200/),min,173.25,39526,DB00312,Pentobarbital
,8403961,plasma concentration,Each patient received phenytoin sufficient to maintain a plasma concentration at 15 micrograms/mL (60 mumol/L) both before and after barbiturate therapy.,Effect of barbiturate therapy on phenytoin pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[μg] / [ml],15,40986,DB00312,Pentobarbital
,8403961,maximum metabolic velocity,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[mg] / [h·l],1.09,40987,DB00312,Pentobarbital
,8403961,maximum metabolic velocity,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[mg] / [h·l],1.77,40988,DB00312,Pentobarbital
,8403961,maximum metabolic velocity,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[nM] / [l·s],1.20,40989,DB00312,Pentobarbital
,8403961,maximum metabolic velocity,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[nM] / [l·s],1.95,40990,DB00312,Pentobarbital
,8403961,area under the plasma concentration-time curve (0 to infinity),"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[mg·min] / [ml],32.5,40991,DB00312,Pentobarbital
,8403961,area under the plasma concentration-time curve (0 to infinity),"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[mg·min] / [ml],8.7,40992,DB00312,Pentobarbital
,8403961,mean residence time,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[mg·min] / [ml],8.7,40993,DB00312,Pentobarbital
,8403961,mean residence time,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[mM·s] / [l],2.14,40994,DB00312,Pentobarbital
,8403961,mean residence time,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),[mM·s] / [l],0.57,40995,DB00312,Pentobarbital
,8403961,mean residence time,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),secs,"135,000",40996,DB00312,Pentobarbital
,8403961,mean residence time,"For total phenytoin, maximum metabolic velocity was increased by 62% (1.09 +/- 0.62 to 1.77 +/- 0.52 mg/L/hr, 1.20 +/- 0.68 to 1.95 +/- 0.57 nmol/L/sec, p < .05), and area under the plasma concentration-time curve (0 to infinity) and mean residence time were each decreased by 73% (32.5 +/- 20.0 to 8.7 +/- 3.1 min.mg/mL, 2.14 +/- 1.25 to 0.57 +/- 0.19 sec.mmol/L, p < .01, and 135,000 +/- 69,000 to 37,000 +/- 11,000 secs, p < .005, respectively) after barbiturate therapy.",Effect of barbiturate therapy on phenytoin pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8403961/),secs,"37,000",40997,DB00312,Pentobarbital
,31761600,CNS-to-plasma ratio,"The CNS-to-plasma ratio of vatinoxan concentration was approximately 1:50, whereas the concentrations of dexmedetomidine and levomedetomidine in the CNS were three- to seven-fold of those in plasma.","Concentrations of medetomidine enantiomers and vatinoxan, an α2-adrenoceptor antagonist, in plasma and central nervous tissue after intravenous coadministration in dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31761600/),,1,46840,DB00312,Pentobarbital
,10360874,effect compartment concentration,"The metocurine effect compartment concentration associated with a 50% diminution of twitch height after 3 weeks was 1,716+/-1,208 ng/ml (mean +/- SD), which was significantly different from 257+/-34 ng/ml, the value on day 0.",Deep sedation and mechanical ventilation without paralysis for 3 weeks in normal beagles: exaggerated resistance to metocurine in gastrocnemius muscle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360874/),[ng] / [ml],"1,716",48194,DB00312,Pentobarbital
,10360874,effect compartment concentration,"The metocurine effect compartment concentration associated with a 50% diminution of twitch height after 3 weeks was 1,716+/-1,208 ng/ml (mean +/- SD), which was significantly different from 257+/-34 ng/ml, the value on day 0.",Deep sedation and mechanical ventilation without paralysis for 3 weeks in normal beagles: exaggerated resistance to metocurine in gastrocnemius muscle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360874/),[ng] / [ml],257,48195,DB00312,Pentobarbital
,8887740,FH,The FH values of diclofenac were 0.664 in group A and 0.643 in group B.,Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),,0.664,54443,DB00312,Pentobarbital
,8887740,FH,The FH values of diclofenac were 0.664 in group A and 0.643 in group B.,Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),,0.643,54444,DB00312,Pentobarbital
,8887740,biliary excretion ratio (Fb),The biliary excretion ratio (Fb) of total diclofenac after intravenous administration was 27.0% in group A and 14.1% in group B.,Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),%,27.0,54445,DB00312,Pentobarbital
,8887740,biliary excretion ratio (Fb),The biliary excretion ratio (Fb) of total diclofenac after intravenous administration was 27.0% in group A and 14.1% in group B.,Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),%,14.1,54446,DB00312,Pentobarbital
,8887740,tb,"The tb values for total diclofenac were estimated to be 0.192 h (intravenous) and 0.159 h (intraportal) in group A, and 0.174 h and 0.238 in group B.",Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),h,0.192,54447,DB00312,Pentobarbital
,8887740,tb,"The tb values for total diclofenac were estimated to be 0.192 h (intravenous) and 0.159 h (intraportal) in group A, and 0.174 h and 0.238 in group B.",Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),h,0.159,54448,DB00312,Pentobarbital
,8887740,tb,"The tb values for total diclofenac were estimated to be 0.192 h (intravenous) and 0.159 h (intraportal) in group A, and 0.174 h and 0.238 in group B.",Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),h,0.174,54449,DB00312,Pentobarbital
,8887740,tb,"The tb values for total diclofenac were estimated to be 0.192 h (intravenous) and 0.159 h (intraportal) in group A, and 0.174 h and 0.238 in group B.",Influence of pentobarbitone on in-vivo local disposition of diclofenac in rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8887740/),,0.238,54450,DB00312,Pentobarbital
,7525528,half-life,"After vehicle, the clearance was monoexponential with a half-life of 153 min.",Biexponential pulmonary clearance of 99mTc-DTPA induced by detergent aerosol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7525528/),min,153,54543,DB00312,Pentobarbital
,7525528,half-life,Detergent induced a biexponential clearance with a rapidly clearing additional pool of radioactivity with a half-life of 5-15 min.,Biexponential pulmonary clearance of 99mTc-DTPA induced by detergent aerosol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7525528/),min,5-15,54544,DB00312,Pentobarbital
,7205126,metabolic clearance rate,The metabolic clearance rate of progesterone was 0.116 l/min and the turn-over time was 0.006 min/ml plasma.,Fate of progesterone in the plasma and various tissues of anaesthetized rabbits. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205126/),[l] / [min],0.116,55003,DB00312,Pentobarbital
,7205126,turn-over time,The metabolic clearance rate of progesterone was 0.116 l/min and the turn-over time was 0.006 min/ml plasma.,Fate of progesterone in the plasma and various tissues of anaesthetized rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205126/),[min] / [ml·plasma],0.006,55004,DB00312,Pentobarbital
,7394315,apparent half-life ((t 1/2),"In a randomized study on nine animals (not crossed over) it was observed that the apparent half-life ((t 1/2) of this drug increased four-fold as dose was increased from 10 to 50 mg/kg (6 1/2 - 64 +/- 42 min vs. 267 +/- 118 min, respectively; mean +/- S.D.).",Dose-dependence of the apparent half-life of phenytoin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7394315/),min,64,55991,DB00312,Pentobarbital
,7394315,6 1/2,"In a randomized study on nine animals (not crossed over) it was observed that the apparent half-life ((t 1/2) of this drug increased four-fold as dose was increased from 10 to 50 mg/kg (6 1/2 - 64 +/- 42 min vs. 267 +/- 118 min, respectively; mean +/- S.D.).",Dose-dependence of the apparent half-life of phenytoin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7394315/),min,64,55992,DB00312,Pentobarbital
,7394315,6 1/2,"In a randomized study on nine animals (not crossed over) it was observed that the apparent half-life ((t 1/2) of this drug increased four-fold as dose was increased from 10 to 50 mg/kg (6 1/2 - 64 +/- 42 min vs. 267 +/- 118 min, respectively; mean +/- S.D.).",Dose-dependence of the apparent half-life of phenytoin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7394315/),min,267,55993,DB00312,Pentobarbital
,7394315,t 1/2,"In a crossover study on three animals, an even larger dose-dependent increase in t 1/2 was observed (37.8 vs. 271 min).",Dose-dependence of the apparent half-life of phenytoin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7394315/),min,37.8,55994,DB00312,Pentobarbital
,7394315,t 1/2,"In a crossover study on three animals, an even larger dose-dependent increase in t 1/2 was observed (37.8 vs. 271 min).",Dose-dependence of the apparent half-life of phenytoin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7394315/),min,271,55995,DB00312,Pentobarbital
,12131552,steady state level,"In nonischemic hearts, clevidipine reached a steady state level in the coronary venous blood of about 30 nM during the infusion.",Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131552/),nM,30,56705,DB00312,Pentobarbital
,12131552,blood clearance,"The mean blood clearance of clevidipine was calculated to be 0.17 l/min per kilogram, and the estimated half-life was 0.5 minute.",Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131552/),[l] / [kg·min],0.17,56706,DB00312,Pentobarbital
,12131552,half-life,"The mean blood clearance of clevidipine was calculated to be 0.17 l/min per kilogram, and the estimated half-life was 0.5 minute.",Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131552/),min,0.5,56707,DB00312,Pentobarbital
,12131552,half-life,"The in vitro half-life in pig blood was 13 minutes, and the corresponding half-life in plasma was 111 minutes.",Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131552/),min,13,56708,DB00312,Pentobarbital
,12131552,half-life,"The in vitro half-life in pig blood was 13 minutes, and the corresponding half-life in plasma was 111 minutes.",Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131552/),min,111,56709,DB00312,Pentobarbital
,8866453,terminal elimination half-life (t1/2),"The terminal elimination half-life (t1/2) for 4'-OHP was 69.4 min, the apparent volume of distribution (Vd) was 3.39 L/kg and the total clearance (Clt) was 53.6 mL/min.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),min,69.4,59495,DB00312,Pentobarbital
,8866453,apparent volume of distribution (Vd),"The terminal elimination half-life (t1/2) for 4'-OHP was 69.4 min, the apparent volume of distribution (Vd) was 3.39 L/kg and the total clearance (Clt) was 53.6 mL/min.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[l] / [kg],3.39,59496,DB00312,Pentobarbital
,8866453,total clearance (Clt),"The terminal elimination half-life (t1/2) for 4'-OHP was 69.4 min, the apparent volume of distribution (Vd) was 3.39 L/kg and the total clearance (Clt) was 53.6 mL/min.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ml] / [min],53.6,59497,DB00312,Pentobarbital
,8866453,steady-state plasma concentrations,"These data were subsequently used to calculate the loading and maintenance doses of 4'-OHP required to produce targeted steady-state plasma concentrations for 4'-OHP of 30, 60, 120, 240 and 480 ng/mL.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ng] / [ml],30,59498,DB00312,Pentobarbital
,8866453,steady-state plasma concentrations,"These data were subsequently used to calculate the loading and maintenance doses of 4'-OHP required to produce targeted steady-state plasma concentrations for 4'-OHP of 30, 60, 120, 240 and 480 ng/mL.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ng] / [ml],60,59499,DB00312,Pentobarbital
,8866453,steady-state plasma concentrations,"These data were subsequently used to calculate the loading and maintenance doses of 4'-OHP required to produce targeted steady-state plasma concentrations for 4'-OHP of 30, 60, 120, 240 and 480 ng/mL.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ng] / [ml],120,59500,DB00312,Pentobarbital
,8866453,steady-state plasma concentrations,"These data were subsequently used to calculate the loading and maintenance doses of 4'-OHP required to produce targeted steady-state plasma concentrations for 4'-OHP of 30, 60, 120, 240 and 480 ng/mL.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ng] / [ml],240,59501,DB00312,Pentobarbital
,8866453,steady-state plasma concentrations,"These data were subsequently used to calculate the loading and maintenance doses of 4'-OHP required to produce targeted steady-state plasma concentrations for 4'-OHP of 30, 60, 120, 240 and 480 ng/mL.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ng] / [ml],480,59502,DB00312,Pentobarbital
,2870155,clearance,"At normothermia (rectal temperature of 37.5 degrees C), pentobarbitone anaesthesia decreased ICG clearance from 8.0 +/- 1.7 ml min-1 (mean +/- s.e.m., n = 3) in the conscious state to 4.3 +/- 0.6 ml min-1 and AC clearance from 4.9 +/- 0.4 ml min-1 to 3.4 +/- 0.3 ml min-1.",The effect of pentobarbitone anaesthesia and hypothermia on the hepatic clearance of indocyanine green and S(-)-acenocoumarol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2870155/),[ml] / [min],8.0,61432,DB00312,Pentobarbital
,2870155,clearance,"At normothermia (rectal temperature of 37.5 degrees C), pentobarbitone anaesthesia decreased ICG clearance from 8.0 +/- 1.7 ml min-1 (mean +/- s.e.m., n = 3) in the conscious state to 4.3 +/- 0.6 ml min-1 and AC clearance from 4.9 +/- 0.4 ml min-1 to 3.4 +/- 0.3 ml min-1.",The effect of pentobarbitone anaesthesia and hypothermia on the hepatic clearance of indocyanine green and S(-)-acenocoumarol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2870155/),[ml] / [min],4.3,61433,DB00312,Pentobarbital
,2870155,clearance,"At normothermia (rectal temperature of 37.5 degrees C), pentobarbitone anaesthesia decreased ICG clearance from 8.0 +/- 1.7 ml min-1 (mean +/- s.e.m., n = 3) in the conscious state to 4.3 +/- 0.6 ml min-1 and AC clearance from 4.9 +/- 0.4 ml min-1 to 3.4 +/- 0.3 ml min-1.",The effect of pentobarbitone anaesthesia and hypothermia on the hepatic clearance of indocyanine green and S(-)-acenocoumarol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2870155/),[ml] / [min],4.9,61434,DB00312,Pentobarbital
,2870155,clearance,"At normothermia (rectal temperature of 37.5 degrees C), pentobarbitone anaesthesia decreased ICG clearance from 8.0 +/- 1.7 ml min-1 (mean +/- s.e.m., n = 3) in the conscious state to 4.3 +/- 0.6 ml min-1 and AC clearance from 4.9 +/- 0.4 ml min-1 to 3.4 +/- 0.3 ml min-1.",The effect of pentobarbitone anaesthesia and hypothermia on the hepatic clearance of indocyanine green and S(-)-acenocoumarol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2870155/),[ml] / [min],3.4,61435,DB00312,Pentobarbital
,2870155,clearances,"Hypothermia further reduced the clearances of the compounds to 0.9 +/- 0.1 and 2.5 +/- 0.2 ml min-1 for ICG and AC, respectively.",The effect of pentobarbitone anaesthesia and hypothermia on the hepatic clearance of indocyanine green and S(-)-acenocoumarol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2870155/),[ml] / [min],0.9,61436,DB00312,Pentobarbital
,2870155,clearances,"Hypothermia further reduced the clearances of the compounds to 0.9 +/- 0.1 and 2.5 +/- 0.2 ml min-1 for ICG and AC, respectively.",The effect of pentobarbitone anaesthesia and hypothermia on the hepatic clearance of indocyanine green and S(-)-acenocoumarol in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2870155/),[ml] / [min],2.5,61437,DB00312,Pentobarbital
,2980368,area under the curve ratio,Fetal concentrations were low compared to maternal concentrations as seen by the small fetal/maternal area under the curve ratio (0.053 +/- 0.006).,A method to obtain maternal-fetal plasma samples using a microsampling technique in the rat: transplacental passage of cefoxitin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2980368/),,0.053,67536,DB00312,Pentobarbital
,8760260,plasma clearance,"It was found that the plasma half-life (min), plasma clearance (ml.kg-1.min-1), and volume of distribution (ml/kg) of ANF were, respectively, 2.5 +/- 4, 115 +/- 19, and 371 +/- 44 in pentobarbital-anesthetized virgin rats (n = 6) and not different from the corresponding values of 3.1 +/- 0.5, 124 +/- 26, and 526 +/- 120 in 20-day gravid animals (n = 6).",Pharmacokinetics and renal metabolism of atrial natriuretic factor during rat pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760260/),[ml] / [kg],2.5,73880,DB00312,Pentobarbital
,8760260,plasma clearance,"It was found that the plasma half-life (min), plasma clearance (ml.kg-1.min-1), and volume of distribution (ml/kg) of ANF were, respectively, 2.5 +/- 4, 115 +/- 19, and 371 +/- 44 in pentobarbital-anesthetized virgin rats (n = 6) and not different from the corresponding values of 3.1 +/- 0.5, 124 +/- 26, and 526 +/- 120 in 20-day gravid animals (n = 6).",Pharmacokinetics and renal metabolism of atrial natriuretic factor during rat pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760260/),[ml] / [kg],3.1,73881,DB00312,Pentobarbital
,8760260,plasma clearance,"It was found that the plasma half-life (min), plasma clearance (ml.kg-1.min-1), and volume of distribution (ml/kg) of ANF were, respectively, 2.5 +/- 4, 115 +/- 19, and 371 +/- 44 in pentobarbital-anesthetized virgin rats (n = 6) and not different from the corresponding values of 3.1 +/- 0.5, 124 +/- 26, and 526 +/- 120 in 20-day gravid animals (n = 6).",Pharmacokinetics and renal metabolism of atrial natriuretic factor during rat pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760260/),,124,73882,DB00312,Pentobarbital
,8760260,plasma clearance,"It was found that the plasma half-life (min), plasma clearance (ml.kg-1.min-1), and volume of distribution (ml/kg) of ANF were, respectively, 2.5 +/- 4, 115 +/- 19, and 371 +/- 44 in pentobarbital-anesthetized virgin rats (n = 6) and not different from the corresponding values of 3.1 +/- 0.5, 124 +/- 26, and 526 +/- 120 in 20-day gravid animals (n = 6).",Pharmacokinetics and renal metabolism of atrial natriuretic factor during rat pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760260/),,526,73883,DB00312,Pentobarbital
,8760260,volume of distribution,"It was found that the plasma half-life (min), plasma clearance (ml.kg-1.min-1), and volume of distribution (ml/kg) of ANF were, respectively, 2.5 +/- 4, 115 +/- 19, and 371 +/- 44 in pentobarbital-anesthetized virgin rats (n = 6) and not different from the corresponding values of 3.1 +/- 0.5, 124 +/- 26, and 526 +/- 120 in 20-day gravid animals (n = 6).",Pharmacokinetics and renal metabolism of atrial natriuretic factor during rat pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760260/),[ml] / [kg],115,73884,DB00312,Pentobarbital
,8760260,volume of distribution,"It was found that the plasma half-life (min), plasma clearance (ml.kg-1.min-1), and volume of distribution (ml/kg) of ANF were, respectively, 2.5 +/- 4, 115 +/- 19, and 371 +/- 44 in pentobarbital-anesthetized virgin rats (n = 6) and not different from the corresponding values of 3.1 +/- 0.5, 124 +/- 26, and 526 +/- 120 in 20-day gravid animals (n = 6).",Pharmacokinetics and renal metabolism of atrial natriuretic factor during rat pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760260/),[ml] / [kg],371,73885,DB00312,Pentobarbital
,8760260,volume of distribution,"It was found that the plasma half-life (min), plasma clearance (ml.kg-1.min-1), and volume of distribution (ml/kg) of ANF were, respectively, 2.5 +/- 4, 115 +/- 19, and 371 +/- 44 in pentobarbital-anesthetized virgin rats (n = 6) and not different from the corresponding values of 3.1 +/- 0.5, 124 +/- 26, and 526 +/- 120 in 20-day gravid animals (n = 6).",Pharmacokinetics and renal metabolism of atrial natriuretic factor during rat pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760260/),[ml] / [kg],3.1,73886,DB00312,Pentobarbital
,8760260,volume of distribution,"It was found that the plasma half-life (min), plasma clearance (ml.kg-1.min-1), and volume of distribution (ml/kg) of ANF were, respectively, 2.5 +/- 4, 115 +/- 19, and 371 +/- 44 in pentobarbital-anesthetized virgin rats (n = 6) and not different from the corresponding values of 3.1 +/- 0.5, 124 +/- 26, and 526 +/- 120 in 20-day gravid animals (n = 6).",Pharmacokinetics and renal metabolism of atrial natriuretic factor during rat pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760260/),,526,73887,DB00312,Pentobarbital
,8760260,Rates of metabolism,"Rates of metabolism of ANF (pmol.min-1.microgram protein-1) by renal cortical membranes from virgin (n = 5) and gravid (n = 5) rats were, respectively, 45 +/- 0.6 and 45 +/- 0.5; likewise, cortical membrane neutral endopeptidase activities in virgin and 20-day gravid rats (n = 7) did not differ.",Pharmacokinetics and renal metabolism of atrial natriuretic factor during rat pregnancy. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760260/),[-1·pM·μg] / [min],45,73888,DB00312,Pentobarbital
,8760260,Rates of metabolism,"Rates of metabolism of ANF (pmol.min-1.microgram protein-1) by renal cortical membranes from virgin (n = 5) and gravid (n = 5) rats were, respectively, 45 +/- 0.6 and 45 +/- 0.5; likewise, cortical membrane neutral endopeptidase activities in virgin and 20-day gravid rats (n = 7) did not differ.",Pharmacokinetics and renal metabolism of atrial natriuretic factor during rat pregnancy. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8760260/),[-1·pM·μg] / [min],45,73889,DB00312,Pentobarbital
,29124481,zeta potentials,"Their mean particle sizes were 127.6 and 155.0 nm, mean zeta potentials were 2.24 and - 18.5 mV, and entrapment efficiencies were 76.31 and 78.40%, respectively.",Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124481/),mv,2.24,78609,DB00312,Pentobarbital
,29124481,zeta potentials,"Their mean particle sizes were 127.6 and 155.0 nm, mean zeta potentials were 2.24 and - 18.5 mV, and entrapment efficiencies were 76.31 and 78.40%, respectively.",Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124481/),mv,-,78610,DB00312,Pentobarbital
,29124481,zeta potentials,"Their mean particle sizes were 127.6 and 155.0 nm, mean zeta potentials were 2.24 and - 18.5 mV, and entrapment efficiencies were 76.31 and 78.40%, respectively.",Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124481/),mv,18.5,78611,DB00312,Pentobarbital
,29124481,entrapment efficiencies,"Their mean particle sizes were 127.6 and 155.0 nm, mean zeta potentials were 2.24 and - 18.5 mV, and entrapment efficiencies were 76.31 and 78.40%, respectively.",Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124481/),%,76.31,78612,DB00312,Pentobarbital
,29124481,entrapment efficiencies,"Their mean particle sizes were 127.6 and 155.0 nm, mean zeta potentials were 2.24 and - 18.5 mV, and entrapment efficiencies were 76.31 and 78.40%, respectively.",Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124481/),%,78.40,78613,DB00312,Pentobarbital
,8780280,total plasma clearance (CL),"After IV bolus, the total plasma clearance (CL) (295 +/- 132 mL/min) and volume of distribution at steady state (Vss) (139 +/- 38.5 L) of R-thiopental were significantly greater than those of S-thiopental (230 +/- 104 mL/min and 114 +/- 47.5 L, respectively).",Pharmacokinetics of thiopental and pentobarbital enantiomers after intravenous administration of racemic thiopental. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780280/),[ml] / [min],295,83910,DB00312,Pentobarbital
,8780280,volume of distribution at steady state (Vss),"After IV bolus, the total plasma clearance (CL) (295 +/- 132 mL/min) and volume of distribution at steady state (Vss) (139 +/- 38.5 L) of R-thiopental were significantly greater than those of S-thiopental (230 +/- 104 mL/min and 114 +/- 47.5 L, respectively).",Pharmacokinetics of thiopental and pentobarbital enantiomers after intravenous administration of racemic thiopental. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780280/),l,139,83911,DB00312,Pentobarbital
,8780280,volume of distribution at steady state (Vss),"After IV bolus, the total plasma clearance (CL) (295 +/- 132 mL/min) and volume of distribution at steady state (Vss) (139 +/- 38.5 L) of R-thiopental were significantly greater than those of S-thiopental (230 +/- 104 mL/min and 114 +/- 47.5 L, respectively).",Pharmacokinetics of thiopental and pentobarbital enantiomers after intravenous administration of racemic thiopental. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780280/),l,114,83912,DB00312,Pentobarbital
,8780280,fu,The fu of R-thiopental (12.4% +/- 0.6%) was significantly greater than that of S-thiopental (10.0% +/- 1.0%).,Pharmacokinetics of thiopental and pentobarbital enantiomers after intravenous administration of racemic thiopental. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780280/),%,12.4,83913,DB00312,Pentobarbital
,8780280,fu,The fu of R-thiopental (12.4% +/- 0.6%) was significantly greater than that of S-thiopental (10.0% +/- 1.0%).,Pharmacokinetics of thiopental and pentobarbital enantiomers after intravenous administration of racemic thiopental. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8780280/),%,10.0,83914,DB00312,Pentobarbital
,8807019,steady-state volume of distribution,Mean steady-state volume of distribution of methohexital in the anesthetized dogs was 1.50 L/kg of body weight and mean elimination clearance was 10.2 ml/kg/min.,Induction and maintenance of anesthesia in dogs by intravenous administration of methohexital. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807019/),[l] / [kg],1.50,84402,DB00312,Pentobarbital
,8807019,elimination clearance,Mean steady-state volume of distribution of methohexital in the anesthetized dogs was 1.50 L/kg of body weight and mean elimination clearance was 10.2 ml/kg/min.,Induction and maintenance of anesthesia in dogs by intravenous administration of methohexital. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807019/),[ml] / [kg·min],10.2,84403,DB00312,Pentobarbital
,3605749,arterial propranolol concentration,"However, there was a rapid increase in arterial propranolol concentration from 88 +/- 10 ng/ml (mean +/- SEM) prior to halothane to 116 +/- 12 ng/ml (P less than 0.05) and 130 +/- 7 ng/ml (P less than 0.05) 60 and 120 min, respectively, after starting halothane anesthesia (2.0 MAC 1.74%).",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),[ng] / [ml],88,88198,DB00312,Pentobarbital
,3605749,arterial propranolol concentration,"However, there was a rapid increase in arterial propranolol concentration from 88 +/- 10 ng/ml (mean +/- SEM) prior to halothane to 116 +/- 12 ng/ml (P less than 0.05) and 130 +/- 7 ng/ml (P less than 0.05) 60 and 120 min, respectively, after starting halothane anesthesia (2.0 MAC 1.74%).",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),[ng] / [ml],116,88199,DB00312,Pentobarbital
,3605749,arterial propranolol concentration,"However, there was a rapid increase in arterial propranolol concentration from 88 +/- 10 ng/ml (mean +/- SEM) prior to halothane to 116 +/- 12 ng/ml (P less than 0.05) and 130 +/- 7 ng/ml (P less than 0.05) 60 and 120 min, respectively, after starting halothane anesthesia (2.0 MAC 1.74%).",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),[ng] / [ml],130,88200,DB00312,Pentobarbital
,3605749,arterial to venous (A/V) concentration ratio,"The increase in venous propranolol concentration lagged substantially behind that of the arterial concentration, so that, 60 min after starting halothane, the arterial to venous (A/V) concentration ratio increased from 1.13 +/- 0.05 to a maximum of 1.48 +/- 0.08.",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),,1.13,88201,DB00312,Pentobarbital
,3605749,arterial to venous (A/V) concentration ratio,"The increase in venous propranolol concentration lagged substantially behind that of the arterial concentration, so that, 60 min after starting halothane, the arterial to venous (A/V) concentration ratio increased from 1.13 +/- 0.05 to a maximum of 1.48 +/- 0.08.",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),,1.48,88202,DB00312,Pentobarbital
,891097,area under the plasma concentration time curve,"The area under the plasma concentration time curve after an oral 200-mg dose decreased from 706 +/- 277 to 154 +/- 48 ng/ml-hr (mean and SD) with the barbiturate treatment, but there was no significant change in elimination rate.",Effect of pentobarbital on the disposition of alprenolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891097/),[ng] / [ml-hr],706,92476,DB00312,Pentobarbital
,891097,area under the plasma concentration time curve,"The area under the plasma concentration time curve after an oral 200-mg dose decreased from 706 +/- 277 to 154 +/- 48 ng/ml-hr (mean and SD) with the barbiturate treatment, but there was no significant change in elimination rate.",Effect of pentobarbital on the disposition of alprenolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891097/),[ng] / [ml-hr],154,92477,DB00312,Pentobarbital
,891097,extraction,The change in area corresponded to an increase in extraction by the liver from 0.72 +/- 0.13 to 0.93 +/- 0.01.,Effect of pentobarbital on the disposition of alprenolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891097/),,0.72,92478,DB00312,Pentobarbital
,891097,extraction,The change in area corresponded to an increase in extraction by the liver from 0.72 +/- 0.13 to 0.93 +/- 0.01.,Effect of pentobarbital on the disposition of alprenolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891097/),,0.93,92479,DB00312,Pentobarbital
,952573,total body clearance (TBC),"Attempts were made to relate pharmacokinetic properties of carbamazepine to its effect on pentobarbital sleeping time and on protection against electroshock, after acute and repeated administration: --it was found that male rats eliminate carbamazepine faster than females: the total body clearance (TBC) was 16 ml/min/kg and 9.4 ml/min/kg, respectively.","Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952573/),[ml] / [kg·min],16,94553,DB00312,Pentobarbital
,952573,total body clearance (TBC),"Attempts were made to relate pharmacokinetic properties of carbamazepine to its effect on pentobarbital sleeping time and on protection against electroshock, after acute and repeated administration: --it was found that male rats eliminate carbamazepine faster than females: the total body clearance (TBC) was 16 ml/min/kg and 9.4 ml/min/kg, respectively.","Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952573/),[ml] / [kg·min],9.4,94554,DB00312,Pentobarbital
,9332467,%ID/ml,"Following the same sequence of groups, the %ID/ml values of platinum in the cumulative urine were 0.001%, 0.619%, 0.184% and 0.118%, respectively.",The effects of anesthesia on the biodistribution of drugs in rats: a carboplatin study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332467/),%,0.001,107259,DB00312,Pentobarbital
,9332467,%ID/ml,"Following the same sequence of groups, the %ID/ml values of platinum in the cumulative urine were 0.001%, 0.619%, 0.184% and 0.118%, respectively.",The effects of anesthesia on the biodistribution of drugs in rats: a carboplatin study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332467/),%,0.619,107260,DB00312,Pentobarbital
,9332467,%ID/ml,"Following the same sequence of groups, the %ID/ml values of platinum in the cumulative urine were 0.001%, 0.619%, 0.184% and 0.118%, respectively.",The effects of anesthesia on the biodistribution of drugs in rats: a carboplatin study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332467/),%,0.184,107261,DB00312,Pentobarbital
,9332467,%ID/ml,"Following the same sequence of groups, the %ID/ml values of platinum in the cumulative urine were 0.001%, 0.619%, 0.184% and 0.118%, respectively.",The effects of anesthesia on the biodistribution of drugs in rats: a carboplatin study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9332467/),%,0.118,107262,DB00312,Pentobarbital
,6842399,elimination-phase half-life,The elimination-phase half-life of pentobarbital was 8.2 +/- 2.2 hr.,Pharmacokinetics of pentobarbital in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842399/),h,8.2,117642,DB00312,Pentobarbital
,6842399,steady-state volume of pentobarbital distribution,The steady-state volume of pentobarbital distribution was 1.08 +/- 0.21 liters/kg and the elimination clearance was 0.0013 +/- 0.0004 liters/min X kg.,Pharmacokinetics of pentobarbital in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842399/),[l] / [kg],1.08,117643,DB00312,Pentobarbital
,6842399,elimination clearance,The steady-state volume of pentobarbital distribution was 1.08 +/- 0.21 liters/kg and the elimination clearance was 0.0013 +/- 0.0004 liters/min X kg.,Pharmacokinetics of pentobarbital in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6842399/),[l] / [kg·min],0.0013,117644,DB00312,Pentobarbital
,1513751,ED50,The ED50 of CRF for reducing pulmonary oedema was 3.2 (1.3-7.4) micrograms/kg s.c.,Epinephrine-induced pulmonary oedema in rats is inhibited by corticotropin-releasing factor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1513751/),[μg] / [kg],3.2,119929,DB00312,Pentobarbital
exceeded,7081435,In ratio,"The stop-flow pattern of MTX excretion was similar, except the base-line flow pattern of MTX excretion was similar, except the base-line (U/P)MTX/(U/P)In ratio exceeded 1.0, indicating net secretion during both free-flow and stopped-flow periods.",Renal tubular transport of folic acid and methotrexate in the monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7081435/),,1.0,123413,DB00312,Pentobarbital
,20444012,terminal elimination rate,Mean in vivo terminal elimination rate of cisatracurium (16.4 +/- 2.7 min) was twofold faster than mean in vitro degradation rate (32.9 +/- 3.7 min) in our dogs.,Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444012/),min,16.4,129247,DB00312,Pentobarbital
,20444012,degradation rate,Mean in vivo terminal elimination rate of cisatracurium (16.4 +/- 2.7 min) was twofold faster than mean in vitro degradation rate (32.9 +/- 3.7 min) in our dogs.,Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444012/),min,32.9,129248,DB00312,Pentobarbital
,20444012,Organ clearance,Organ clearance was 6.12 +/- 1.69 mL/min.kg and accounted for 56 +/- 12% of the total body clearance.,Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444012/),[ml] / [kg·min],6.12,129249,DB00312,Pentobarbital
,20444012,Apparent volume of distribution,"Apparent volume of distribution, an exit site-dependent parameter, averaged 212 or 184 mL/kg whether or not peripheral elimination was accounted for in the model.",Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444012/),[ml] / [kg],212,129250,DB00312,Pentobarbital
,20444012,Apparent volume of distribution,"Apparent volume of distribution, an exit site-dependent parameter, averaged 212 or 184 mL/kg whether or not peripheral elimination was accounted for in the model.",Studies on the pharmacokinetics of cisatracurium in anesthetized dogs: in vitro-in vivo correlations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20444012/),[ml] / [kg],184,129251,DB00312,Pentobarbital
,3049339,half-life,"Plasma disappearance of the exogenously administered 125I-rh-renin in marmosets (n = 6) showed two exponential components, with a half-life of 12.1 +/- 1.9 minutes for the rapid component and 120.3 +/- 16.4 minutes for the slow component.",Fate of recombinant human renin administered exogenously to anesthetized monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3049339/),min,12.1,133987,DB00312,Pentobarbital
,3049339,half-life,"Plasma disappearance of the exogenously administered 125I-rh-renin in marmosets (n = 6) showed two exponential components, with a half-life of 12.1 +/- 1.9 minutes for the rapid component and 120.3 +/- 16.4 minutes for the slow component.",Fate of recombinant human renin administered exogenously to anesthetized monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3049339/),min,120.3,133988,DB00312,Pentobarbital
,3049339,metabolic clearance rate,The metabolic clearance rate was 1.17 +/- 0.26 ml/min/kg.,Fate of recombinant human renin administered exogenously to anesthetized monkeys. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3049339/),[ml] / [kg·min],1.17,133989,DB00312,Pentobarbital
,3795049,hepatic extraction ratio,"The rate-limiting step in the clearance of BIU from blood most likely is glutathione conjugation as it was shown that rate-limitation is not due to flow-limited clearance in the liver (the initial extraction ratio of BIU in the perfused liver preparation was low: hepatic extraction ratio = 0.23), protein binding (60% was unbound in plasma) or enzyme saturation (linear pharmacokinetics in the dose range studied: 22-270 mumol/kg).",alpha-Bromoisovalerylurea as model substrate for studies on pharmacokinetics of glutathione conjugation in the rat. Pharmacokinetics and stereoselectivity of metabolism and excretion in vivo and in the perfused liver. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795049/),,0.23,136503,DB00312,Pentobarbital
,3795049,protein binding,"The rate-limiting step in the clearance of BIU from blood most likely is glutathione conjugation as it was shown that rate-limitation is not due to flow-limited clearance in the liver (the initial extraction ratio of BIU in the perfused liver preparation was low: hepatic extraction ratio = 0.23), protein binding (60% was unbound in plasma) or enzyme saturation (linear pharmacokinetics in the dose range studied: 22-270 mumol/kg).",alpha-Bromoisovalerylurea as model substrate for studies on pharmacokinetics of glutathione conjugation in the rat. Pharmacokinetics and stereoselectivity of metabolism and excretion in vivo and in the perfused liver. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3795049/),%,60,136504,DB00312,Pentobarbital
,2618087,biological half-life (t 1/2),"The biological half-life (t 1/2) of N,N'-diallylpentobarbital (DAPB) in brain after i.p. injection to mouse was 96 min (first phase) and 11 h (second phase).","N,N'-diallylpentobarbital (DAPB) metabolites and their effects on pentobarbital-induced sleep and hepatic drug-metabolizing enzymes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618087/),min,96,141383,DB00312,Pentobarbital
,2618087,biological half-life (t 1/2),"The biological half-life (t 1/2) of N,N'-diallylpentobarbital (DAPB) in brain after i.p. injection to mouse was 96 min (first phase) and 11 h (second phase).","N,N'-diallylpentobarbital (DAPB) metabolites and their effects on pentobarbital-induced sleep and hepatic drug-metabolizing enzymes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618087/),h,11,141384,DB00312,Pentobarbital
,2618087,t 1/2,"The t 1/2 values in plasma were 102 min and 9.4 h, respectively, after i.p. injection.","N,N'-diallylpentobarbital (DAPB) metabolites and their effects on pentobarbital-induced sleep and hepatic drug-metabolizing enzymes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618087/),min,102,141385,DB00312,Pentobarbital
,2618087,t 1/2,"The t 1/2 values in plasma were 102 min and 9.4 h, respectively, after i.p. injection.","N,N'-diallylpentobarbital (DAPB) metabolites and their effects on pentobarbital-induced sleep and hepatic drug-metabolizing enzymes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618087/),h,9.4,141386,DB00312,Pentobarbital
,2618087,t 1/2,"After intracerebroventricular (i.c.v.) administration, the t 1/2 values in brain and plasma were 18 and 120 min, and 42 and 177 min, respectively.","N,N'-diallylpentobarbital (DAPB) metabolites and their effects on pentobarbital-induced sleep and hepatic drug-metabolizing enzymes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618087/),min,18,141387,DB00312,Pentobarbital
,2618087,t 1/2,"After intracerebroventricular (i.c.v.) administration, the t 1/2 values in brain and plasma were 18 and 120 min, and 42 and 177 min, respectively.","N,N'-diallylpentobarbital (DAPB) metabolites and their effects on pentobarbital-induced sleep and hepatic drug-metabolizing enzymes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618087/),min,120,141388,DB00312,Pentobarbital
,2618087,t 1/2,"After intracerebroventricular (i.c.v.) administration, the t 1/2 values in brain and plasma were 18 and 120 min, and 42 and 177 min, respectively.","N,N'-diallylpentobarbital (DAPB) metabolites and their effects on pentobarbital-induced sleep and hepatic drug-metabolizing enzymes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618087/),min,42,141389,DB00312,Pentobarbital
,2618087,t 1/2,"After intracerebroventricular (i.c.v.) administration, the t 1/2 values in brain and plasma were 18 and 120 min, and 42 and 177 min, respectively.","N,N'-diallylpentobarbital (DAPB) metabolites and their effects on pentobarbital-induced sleep and hepatic drug-metabolizing enzymes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618087/),min,177,141390,DB00312,Pentobarbital
,26935349,concentration ratio,"Average TD tonsil concentrations increased significantly in a dose-dependent manner, and the tonsil TD vs. plasma TD concentration ratio was approximately 75 for the doses of 2 and 4 mg of TD/kg bw at 24 h post-treatment.",Pharmacokinetics of tildipirosin in pig tonsils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26935349/),,75,143460,DB00312,Pentobarbital
,26935349,ratio AUCtonsil/AUCplasma,"Finally, the ratio AUCtonsil/AUCplasma was 97.9, and the T1/2 (h) was clearly higher in tonsil than in plasma.",Pharmacokinetics of tildipirosin in pig tonsils. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26935349/),,97.9,143461,DB00312,Pentobarbital
,2017787,Blood clearance,Blood clearance averaged 201 ml.min-1.kg-1 body wt.,Percutaneous uptake and kinetics of methyl isobutyl ketone (MIBK) in the guinea-pig. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2017787/),[ml] / [kg·min],201,150288,DB00312,Pentobarbital
,2017787,maximum percutaneous uptake,A maximum percutaneous uptake of 1.1 mumol.min-1.cm-2 was reached 10-45 min after the onset of exposure and decreased to 0.56 mumol.,Percutaneous uptake and kinetics of methyl isobutyl ketone (MIBK) in the guinea-pig. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2017787/),[μM] / [(cm)^2·min],1.1,150289,DB00312,Pentobarbital
,2017787,maximum percutaneous uptake,A maximum percutaneous uptake of 1.1 mumol.min-1.cm-2 was reached 10-45 min after the onset of exposure and decreased to 0.56 mumol.,Percutaneous uptake and kinetics of methyl isobutyl ketone (MIBK) in the guinea-pig. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2017787/),μM,0.56,150290,DB00312,Pentobarbital
,847291,plasma clearance (C1p),"Pharmacokinetic linearity was evidenced by a mean plasma clearance (C1p) of 1.81 ml/(kg x min), with a coefficient of variation of 16.6%, and a range of 1.51 to 2.36 for all experiments, and, a linear relationship between total area under the curve (AUC) and mg/kg dose in cat ""4 given doses of 12.5, 25 and 50 mg/kg.",Pharmacokinetics of peniobarbital in the cat and comparisons with the rabbit and man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/847291/),[ml] / [kg·min],1.81,154882,DB00312,Pentobarbital
,847291,"apparent elimination half-life, (t1/2)beta'","However, the apparent elimination half-life, (t1/2)beta' averaged 4.87 hr, with a coefficient of variation of 40.7%, and range of 1.80 to 7.52 in all experiments, and, in cat ""4 the half-life was the same, namely 7.5 hr following the two higher doses, but lower, namely 4.7 hr, after the lowest dose.",Pharmacokinetics of peniobarbital in the cat and comparisons with the rabbit and man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/847291/),h,4.87,154883,DB00312,Pentobarbital
,847291,half-life,"However, the apparent elimination half-life, (t1/2)beta' averaged 4.87 hr, with a coefficient of variation of 40.7%, and range of 1.80 to 7.52 in all experiments, and, in cat ""4 the half-life was the same, namely 7.5 hr following the two higher doses, but lower, namely 4.7 hr, after the lowest dose.",Pharmacokinetics of peniobarbital in the cat and comparisons with the rabbit and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/847291/),h,7.5,154884,DB00312,Pentobarbital
,847291,half-life,"However, the apparent elimination half-life, (t1/2)beta' averaged 4.87 hr, with a coefficient of variation of 40.7%, and range of 1.80 to 7.52 in all experiments, and, in cat ""4 the half-life was the same, namely 7.5 hr following the two higher doses, but lower, namely 4.7 hr, after the lowest dose.",Pharmacokinetics of peniobarbital in the cat and comparisons with the rabbit and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/847291/),h,4.7,154885,DB00312,Pentobarbital
,1949032,rate of biliary excretion,The rate of biliary excretion of radioactivity was slightly greater for TCDD than TBDD (10% vs 7% in 5 hr).,"Disposition of 2,3,7,8-tetrabromodibenzo-p-dioxin and 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat: biliary excretion and induction of cytochromes CYP1A1 and CYP1A2. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1949032/),%,10,159444,DB00312,Pentobarbital
,1949032,rate of biliary excretion,The rate of biliary excretion of radioactivity was slightly greater for TCDD than TBDD (10% vs 7% in 5 hr).,"Disposition of 2,3,7,8-tetrabromodibenzo-p-dioxin and 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat: biliary excretion and induction of cytochromes CYP1A1 and CYP1A2. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1949032/),%,7,159445,DB00312,Pentobarbital
,1949032,ED50,"The ED50 value for CYP1A1 induction (measured by ethoxyresorufin O-deethylase activity and radioimmunoassay (RIA) was estimated to be 0.8-1.0 nmol/kg, similar to what has been reported for TCDD.","Disposition of 2,3,7,8-tetrabromodibenzo-p-dioxin and 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat: biliary excretion and induction of cytochromes CYP1A1 and CYP1A2. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1949032/),[nM] / [kg],0.8-1.0,159446,DB00312,Pentobarbital
,1696652,distribution half-life,"The distribution half-life was 7.8 +/- 1.7 min (mean +/- SEM), and the elimination half-life was 51.1 +/- 5.9 min; the central compartment volume of distribution (Vc) was 81 +/- 26 ml/kg and the steady-state volume of distribution was 156 +/- 20 ml/kg.",Pharmacokinetics of recombinant human superoxide dismutase. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1696652/),min,7.8,167530,DB00312,Pentobarbital
,1696652,elimination half-life,"The distribution half-life was 7.8 +/- 1.7 min (mean +/- SEM), and the elimination half-life was 51.1 +/- 5.9 min; the central compartment volume of distribution (Vc) was 81 +/- 26 ml/kg and the steady-state volume of distribution was 156 +/- 20 ml/kg.",Pharmacokinetics of recombinant human superoxide dismutase. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1696652/),min,51.1,167531,DB00312,Pentobarbital
,1696652,central compartment volume of distribution (Vc),"The distribution half-life was 7.8 +/- 1.7 min (mean +/- SEM), and the elimination half-life was 51.1 +/- 5.9 min; the central compartment volume of distribution (Vc) was 81 +/- 26 ml/kg and the steady-state volume of distribution was 156 +/- 20 ml/kg.",Pharmacokinetics of recombinant human superoxide dismutase. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1696652/),[ml] / [kg],81,167532,DB00312,Pentobarbital
,1696652,steady-state volume of distribution,"The distribution half-life was 7.8 +/- 1.7 min (mean +/- SEM), and the elimination half-life was 51.1 +/- 5.9 min; the central compartment volume of distribution (Vc) was 81 +/- 26 ml/kg and the steady-state volume of distribution was 156 +/- 20 ml/kg.",Pharmacokinetics of recombinant human superoxide dismutase. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1696652/),[ml] / [kg],156,167533,DB00312,Pentobarbital
,1696652,Peak plasma concentrations,"Peak plasma concentrations (micrograms/ml) for the dosage regimens were (a) 65 +/- 28, (b) 89 +/- 19, (c) 214 +/- 61, (d) 20 +/- 5, and (e) 86 +/- 9.",Pharmacokinetics of recombinant human superoxide dismutase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1696652/),[μg] / [ml],65,167534,DB00312,Pentobarbital
,1696652,Peak plasma concentrations,"Peak plasma concentrations (micrograms/ml) for the dosage regimens were (a) 65 +/- 28, (b) 89 +/- 19, (c) 214 +/- 61, (d) 20 +/- 5, and (e) 86 +/- 9.",Pharmacokinetics of recombinant human superoxide dismutase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1696652/),[μg] / [ml],89,167535,DB00312,Pentobarbital
,1696652,Peak plasma concentrations,"Peak plasma concentrations (micrograms/ml) for the dosage regimens were (a) 65 +/- 28, (b) 89 +/- 19, (c) 214 +/- 61, (d) 20 +/- 5, and (e) 86 +/- 9.",Pharmacokinetics of recombinant human superoxide dismutase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1696652/),[μg] / [ml],214,167536,DB00312,Pentobarbital
,1696652,Peak plasma concentrations,"Peak plasma concentrations (micrograms/ml) for the dosage regimens were (a) 65 +/- 28, (b) 89 +/- 19, (c) 214 +/- 61, (d) 20 +/- 5, and (e) 86 +/- 9.",Pharmacokinetics of recombinant human superoxide dismutase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1696652/),[μg] / [ml],20,167537,DB00312,Pentobarbital
,1696652,Peak plasma concentrations,"Peak plasma concentrations (micrograms/ml) for the dosage regimens were (a) 65 +/- 28, (b) 89 +/- 19, (c) 214 +/- 61, (d) 20 +/- 5, and (e) 86 +/- 9.",Pharmacokinetics of recombinant human superoxide dismutase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1696652/),[μg] / [ml],86,167538,DB00312,Pentobarbital
,7825554,Initial drug levels,"Initial drug levels in nine and 12 blood samples were 0.26-1.85 and 4.08-23.98 mg/L, with highest concentrations in the pulmonary veins.",Postmortem redistribution and degradation of dothiepin. Human case studies and an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7825554/),,0.26-1.85,171507,DB00312,Pentobarbital
,7825554,Initial drug levels,"Initial drug levels in nine and 12 blood samples were 0.26-1.85 and 4.08-23.98 mg/L, with highest concentrations in the pulmonary veins.",Postmortem redistribution and degradation of dothiepin. Human case studies and an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7825554/),,4.08-23.98,171508,DB00312,Pentobarbital
,7825554,Pulmonary artery concentrations,"Pulmonary artery concentrations rose markedly over 18 h: 0.32 rising to 0.9, and 6.54 rising to 19.53 mg/L.",Postmortem redistribution and degradation of dothiepin. Human case studies and an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7825554/),[mg] / [l],0.32,171509,DB00312,Pentobarbital
,7825554,Pulmonary artery concentrations,"Pulmonary artery concentrations rose markedly over 18 h: 0.32 rising to 0.9, and 6.54 rising to 19.53 mg/L.",Postmortem redistribution and degradation of dothiepin. Human case studies and an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7825554/),[mg] / [l],0.9,171510,DB00312,Pentobarbital
,7825554,Pulmonary artery concentrations,"Pulmonary artery concentrations rose markedly over 18 h: 0.32 rising to 0.9, and 6.54 rising to 19.53 mg/L.",Postmortem redistribution and degradation of dothiepin. Human case studies and an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7825554/),[mg] / [l],6.54,171511,DB00312,Pentobarbital
,7825554,Pulmonary artery concentrations,"Pulmonary artery concentrations rose markedly over 18 h: 0.32 rising to 0.9, and 6.54 rising to 19.53 mg/L.",Postmortem redistribution and degradation of dothiepin. Human case studies and an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7825554/),[mg] / [l],19.53,171512,DB00312,Pentobarbital
,15653707,apparent volume of distribution at steady-state (V(ss)),"Remifentanil PK-PD parameters based on theta wave activity were as follows: apparent volume of distribution at steady-state (V(ss)) (231+/-37 ml kg(-1)), total body clearance (Cl) (63+/-16 ml min(-1) kg(-1)), terminal elimination half-life (t(1/2 beta)) (7.71 min), effect compartment concentration at 50% of maximal observed effect (EC(50)) (21+/-13 ng ml(-1)), and equilibration rate constant between plasma and effect compartment (k(e0)) (0.48+/-0.24 min).",Impact of peripheral elimination on the concentration-effect relationship of remifentanil in anaesthetized dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653707/),[ml] / [kg],231,171650,DB00312,Pentobarbital
,15653707,total body clearance (Cl),"Remifentanil PK-PD parameters based on theta wave activity were as follows: apparent volume of distribution at steady-state (V(ss)) (231+/-37 ml kg(-1)), total body clearance (Cl) (63+/-16 ml min(-1) kg(-1)), terminal elimination half-life (t(1/2 beta)) (7.71 min), effect compartment concentration at 50% of maximal observed effect (EC(50)) (21+/-13 ng ml(-1)), and equilibration rate constant between plasma and effect compartment (k(e0)) (0.48+/-0.24 min).",Impact of peripheral elimination on the concentration-effect relationship of remifentanil in anaesthetized dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653707/),[ml] / [kg·min],63,171651,DB00312,Pentobarbital
,15653707,terminal elimination half-life (t(1/2 beta)),"Remifentanil PK-PD parameters based on theta wave activity were as follows: apparent volume of distribution at steady-state (V(ss)) (231+/-37 ml kg(-1)), total body clearance (Cl) (63+/-16 ml min(-1) kg(-1)), terminal elimination half-life (t(1/2 beta)) (7.71 min), effect compartment concentration at 50% of maximal observed effect (EC(50)) (21+/-13 ng ml(-1)), and equilibration rate constant between plasma and effect compartment (k(e0)) (0.48+/-0.24 min).",Impact of peripheral elimination on the concentration-effect relationship of remifentanil in anaesthetized dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653707/),min,7.71,171652,DB00312,Pentobarbital
,15653707,effect compartment concentration at 50% of maximal observed effect (EC(50)),"Remifentanil PK-PD parameters based on theta wave activity were as follows: apparent volume of distribution at steady-state (V(ss)) (231+/-37 ml kg(-1)), total body clearance (Cl) (63+/-16 ml min(-1) kg(-1)), terminal elimination half-life (t(1/2 beta)) (7.71 min), effect compartment concentration at 50% of maximal observed effect (EC(50)) (21+/-13 ng ml(-1)), and equilibration rate constant between plasma and effect compartment (k(e0)) (0.48+/-0.24 min).",Impact of peripheral elimination on the concentration-effect relationship of remifentanil in anaesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653707/),[ng] / [ml],21,171653,DB00312,Pentobarbital
,15653707,steady-state cerebrospinal fluid concentration,"The mean steady-state cerebrospinal fluid concentration of 236 ng ml(-1) represented 52 and 74% of that in arterial and venous blood, respectively.",Impact of peripheral elimination on the concentration-effect relationship of remifentanil in anaesthetized dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15653707/),[ng] / [ml],236,171654,DB00312,Pentobarbital
,2874974,half-life,"Minimal impairment of psychomotor skills and mental acuity occurs in the morning after a bedtime dose of zopiclone, which has a short half-life of about 5 hours and no long acting metabolites.",Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2874974/),h,5,173477,DB00312,Pentobarbital
,6378605,spillover rate into plasma,"As measured with the isotope dilution method using steady state kinetics, basal NE spillover rate into plasma was 203 +/- 92 ng/min; this level fell by 91 +/- 2% (P less than 0.001) to 24 +/- 13 ng/min during anesthesia.",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[ng] / [min],203,174251,DB00312,Pentobarbital
,6378605,spillover rate into plasma,"As measured with the isotope dilution method using steady state kinetics, basal NE spillover rate into plasma was 203 +/- 92 ng/min; this level fell by 91 +/- 2% (P less than 0.001) to 24 +/- 13 ng/min during anesthesia.",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[ng] / [min],24,174252,DB00312,Pentobarbital
,6378605,clearance rate,"Before pentobarbital administration, the NE clearance rate from plasma was 1.7 +/- 0.4 liters/min; this rate fell during anesthesia by 71 +/- 6% (P less than 0.001) to 0.5 +/- 0.2 liters/min.",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[l] / [min],1.7,174253,DB00312,Pentobarbital
,6378605,clearance rate,"Before pentobarbital administration, the NE clearance rate from plasma was 1.7 +/- 0.4 liters/min; this rate fell during anesthesia by 71 +/- 6% (P less than 0.001) to 0.5 +/- 0.2 liters/min.",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[l] / [min],0.5,174254,DB00312,Pentobarbital
,6378605,spillover rate into plasma,"During control studies in which no barbiturate was administered, there was no change in plasma NE levels (111 +/- 11 vs. 116 +/- 19 pg/ml; n = 3), NE spillover rate into plasma (209 +/- 56 vs. 204 +/- 61 ng/min), or clearance of NE from plasma (1.8 +/- 0.4 vs. 1.7 +/- 0.2 liters/min).",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[ng] / [min],209,174255,DB00312,Pentobarbital
,6378605,spillover rate into plasma,"During control studies in which no barbiturate was administered, there was no change in plasma NE levels (111 +/- 11 vs. 116 +/- 19 pg/ml; n = 3), NE spillover rate into plasma (209 +/- 56 vs. 204 +/- 61 ng/min), or clearance of NE from plasma (1.8 +/- 0.4 vs. 1.7 +/- 0.2 liters/min).",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[ng] / [min],204,174256,DB00312,Pentobarbital
,6378605,clearance of,"During control studies in which no barbiturate was administered, there was no change in plasma NE levels (111 +/- 11 vs. 116 +/- 19 pg/ml; n = 3), NE spillover rate into plasma (209 +/- 56 vs. 204 +/- 61 ng/min), or clearance of NE from plasma (1.8 +/- 0.4 vs. 1.7 +/- 0.2 liters/min).",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[l] / [min],1.8,174257,DB00312,Pentobarbital
,6378605,clearance of,"During control studies in which no barbiturate was administered, there was no change in plasma NE levels (111 +/- 11 vs. 116 +/- 19 pg/ml; n = 3), NE spillover rate into plasma (209 +/- 56 vs. 204 +/- 61 ng/min), or clearance of NE from plasma (1.8 +/- 0.4 vs. 1.7 +/- 0.2 liters/min).",Effect of pentobarbital anesthesia on plasma norepinephrine kinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378605/),[l] / [min],1.7,174258,DB00312,Pentobarbital
,1379967,elimination half-lives,"In humans, widely different pharmacokinetic profiles for various biological effects were observed, with relatively short elimination half-lives for the anti-IIa and IIaGI activities of 4.3 +/- 3.5 and 6.7 +/- 3.2 h, respectively, but a relatively long elimination half-life of anti-Xa activity of 24.5 +/- 9.6 h.",Pharmacokinetic considerations on Orgaran (Org 10172) therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379967/),h,4.3,174918,DB00312,Pentobarbital
,1379967,elimination half-lives,"In humans, widely different pharmacokinetic profiles for various biological effects were observed, with relatively short elimination half-lives for the anti-IIa and IIaGI activities of 4.3 +/- 3.5 and 6.7 +/- 3.2 h, respectively, but a relatively long elimination half-life of anti-Xa activity of 24.5 +/- 9.6 h.",Pharmacokinetic considerations on Orgaran (Org 10172) therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379967/),h,6.7,174919,DB00312,Pentobarbital
,1379967,elimination half-life,"In humans, widely different pharmacokinetic profiles for various biological effects were observed, with relatively short elimination half-lives for the anti-IIa and IIaGI activities of 4.3 +/- 3.5 and 6.7 +/- 3.2 h, respectively, but a relatively long elimination half-life of anti-Xa activity of 24.5 +/- 9.6 h.",Pharmacokinetic considerations on Orgaran (Org 10172) therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379967/),h,24.5,174920,DB00312,Pentobarbital
,1379967,Absorption,"Absorption from subcutaneous tissues was found to be close to 100%, which is significantly higher than of heparin; a finding which indicates that the subcutaneous route is reliable for the administration of Orgaran.",Pharmacokinetic considerations on Orgaran (Org 10172) therapy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379967/),%,100,174921,DB00312,Pentobarbital
,94409,half-time,Median serum digitoxin half-time was 5.7 hr.,Correlation between pharmacokinetics and intropic and electrophysiologic responses to digitoxin in the intact dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/94409/),h,5.7,182551,DB00312,Pentobarbital
,7175729,distribution half-life,Pharmacokinetics of bretylium in dogs could be characterized by a two-compartment open model with a distribution half-life of 7 min and biological half-life of 15.9 +/- 1.9 hr.,Pharmacokinetics of bretylium in dogs and the effect of hemoperfusion on elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175729/),min,7,182721,DB00312,Pentobarbital
,7175729,biological half-life,Pharmacokinetics of bretylium in dogs could be characterized by a two-compartment open model with a distribution half-life of 7 min and biological half-life of 15.9 +/- 1.9 hr.,Pharmacokinetics of bretylium in dogs and the effect of hemoperfusion on elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175729/),h,15.9,182722,DB00312,Pentobarbital
,7175729,Plasma levels,Plasma levels declined rapidly from approximately 20 microgram/ml at 6 min to less than 2 microgram/ml within 1 hr.,Pharmacokinetics of bretylium in dogs and the effect of hemoperfusion on elimination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175729/),[μg] / [ml],20,182723,DB00312,Pentobarbital
less,7175729,Plasma levels,Plasma levels declined rapidly from approximately 20 microgram/ml at 6 min to less than 2 microgram/ml within 1 hr.,Pharmacokinetics of bretylium in dogs and the effect of hemoperfusion on elimination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175729/),[μg] / [ml],2,182724,DB00312,Pentobarbital
,7175729,"ratio of intercompartmental rate constants, k12/k21","The ratio of intercompartmental rate constants, k12/k21, was 16.7, and the volume of the central compartment and apparent volume of distribution were 0.245 and 5.22 liter/kg, respectively, indicating a wide distribution of bretylium into the tissues.",Pharmacokinetics of bretylium in dogs and the effect of hemoperfusion on elimination. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175729/),,16.7,182725,DB00312,Pentobarbital
,7175729,volume of the central compartment,"The ratio of intercompartmental rate constants, k12/k21, was 16.7, and the volume of the central compartment and apparent volume of distribution were 0.245 and 5.22 liter/kg, respectively, indicating a wide distribution of bretylium into the tissues.",Pharmacokinetics of bretylium in dogs and the effect of hemoperfusion on elimination. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175729/),[l] / [kg],0.245,182726,DB00312,Pentobarbital
,7175729,volume of the central compartment,"The ratio of intercompartmental rate constants, k12/k21, was 16.7, and the volume of the central compartment and apparent volume of distribution were 0.245 and 5.22 liter/kg, respectively, indicating a wide distribution of bretylium into the tissues.",Pharmacokinetics of bretylium in dogs and the effect of hemoperfusion on elimination. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175729/),[l] / [kg],5.22,182727,DB00312,Pentobarbital
,7175729,apparent volume of distribution,"The ratio of intercompartmental rate constants, k12/k21, was 16.7, and the volume of the central compartment and apparent volume of distribution were 0.245 and 5.22 liter/kg, respectively, indicating a wide distribution of bretylium into the tissues.",Pharmacokinetics of bretylium in dogs and the effect of hemoperfusion on elimination. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175729/),[l] / [kg],5.22,182728,DB00312,Pentobarbital
,7175729,Plasma dialysis clearance,"Plasma dialysis clearance averaged 29.7 ml/min, which is 30% of the total body clearance (98.8 ml/ min).",Pharmacokinetics of bretylium in dogs and the effect of hemoperfusion on elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175729/),[ml] / [min],29.7,182729,DB00312,Pentobarbital
,7175729,total body clearance,"Plasma dialysis clearance averaged 29.7 ml/min, which is 30% of the total body clearance (98.8 ml/ min).",Pharmacokinetics of bretylium in dogs and the effect of hemoperfusion on elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175729/),[ml] / [min],98.8,182730,DB00312,Pentobarbital
,1490484,half-life,"On the basis of statistical criteria a two-compartment model was chosen as the most appropriate for fitting the plasma concentration data, establishing a mean half-life value of the slow disposition phase at around 13 min.",Pharmacokinetic parameters from data relating to the plasma and biliary excretion kinetics of cefmetazole in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490484/),min,13,183686,DB00312,Pentobarbital
,1490484,biliary excretion constant,Analysis of the plasma and biliary data revealed a mean value for the biliary excretion constant of 0.049 l/min and 0.113 l/min for the urinary excretion constant.,Pharmacokinetic parameters from data relating to the plasma and biliary excretion kinetics of cefmetazole in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490484/),[l] / [min],0.049,183687,DB00312,Pentobarbital
,1490484,urinary excretion constant,Analysis of the plasma and biliary data revealed a mean value for the biliary excretion constant of 0.049 l/min and 0.113 l/min for the urinary excretion constant.,Pharmacokinetic parameters from data relating to the plasma and biliary excretion kinetics of cefmetazole in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1490484/),[l] / [min],0.113,183688,DB00312,Pentobarbital
,31237691,Peak BECs,"Peak BECs were 34 and 87 mg/dl for 0.5 and 1.0 g/kg doses, respectively, and occurred at 66 and 87 minutes following gavage.",Discriminative Stimulus Effects and Metabolism of Ethanol in Rhesus Monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31237691/),[mg] / [dl],34,183696,DB00312,Pentobarbital
,31237691,Peak BECs,"Peak BECs were 34 and 87 mg/dl for 0.5 and 1.0 g/kg doses, respectively, and occurred at 66 and 87 minutes following gavage.",Discriminative Stimulus Effects and Metabolism of Ethanol in Rhesus Monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31237691/),[mg] / [dl],87,183697,DB00312,Pentobarbital
,31237691,ED50,"All GABAA and NMDA ligands tested resulted in responding on the EtOH-appropriate lever with the potency ranking of MK-801 (ED50 : 0.017 mg/kg) > midazolam (ED50 : 1.6 mg/kg) > pentobarbital (ED50 : 3.7 mg/kg) > EtOH (ED50 : 700 mg/kg, or 0.7 g/kg) in these subjects.",Discriminative Stimulus Effects and Metabolism of Ethanol in Rhesus Monkeys. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31237691/),[mg] / [kg],0.017,183698,DB00312,Pentobarbital
,19807971,time to death,"Retroorbital ketamine-xylazine was the most efficient and consistent of the 3 methods, with an average time to death of approximately 5 s after injection.",Euthanasia method for mice in rapid time-course pulmonary pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19807971/),s,5,186290,DB00312,Pentobarbital
,10369622,Apparent volume of distribution (Vd),Apparent volume of distribution (Vd) following a 20 mg/kg loading dose was 0.29 L/kg.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[l] / [kg],0.29,190062,DB00312,Pentobarbital
,10369622,steady-state total concentrations,Maintenance infusions of 4-6 mg/kg/h produced steady-state total concentrations of 66 mg/L and 92.4 mg/L (unbound concentration 44.6 mg/L).,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],66,190063,DB00312,Pentobarbital
,10369622,steady-state total concentrations,Maintenance infusions of 4-6 mg/kg/h produced steady-state total concentrations of 66 mg/L and 92.4 mg/L (unbound concentration 44.6 mg/L).,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],92.4,190064,DB00312,Pentobarbital
,10369622,unbound concentration,Maintenance infusions of 4-6 mg/kg/h produced steady-state total concentrations of 66 mg/L and 92.4 mg/L (unbound concentration 44.6 mg/L).,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],44.6,190065,DB00312,Pentobarbital
,10369622,Clearance,Clearance ranged from 63-66 mL/h/kg.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[ml] / [h·kg],63-66,190066,DB00312,Pentobarbital
,10369622,Total,"Total and unbound steady-state VPA concentrations were 32.9 mg/L and 21.2 mg/L, respectively.",Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],32.9,190067,DB00312,Pentobarbital
,10369622,unbound steady-state VPA concentrations,"Total and unbound steady-state VPA concentrations were 32.9 mg/L and 21.2 mg/L, respectively.",Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),[mg] / [l],21.2,190068,DB00312,Pentobarbital
,10369622,Unbound fractions,Unbound fractions (48.3% and 66%) were significantly higher than normal.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),%,48.3,190069,DB00312,Pentobarbital
,10369622,Unbound fractions,Unbound fractions (48.3% and 66%) were significantly higher than normal.,Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10369622/),%,66,190070,DB00312,Pentobarbital
less,3456242,elimination half-life,"When mitozolomide was administered i.p. to mice, drug disposition appeared to fit a simple, one-compartment kinetic model with an elimination half-life of less than 1 h.",Plasma and tissue disposition of mitozolomide in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3456242/),h,1,191502,DB00312,Pentobarbital
,2301762,clearance (CLs),"However, intravenous (iv) morphine clearance (CLs) decreased (P less than 0.05) by 40% from 963 +/- 131 to 579 +/- 91 ml/min during halothane anesthesia, accompanied by an increase (P less than 0.05) in half-life from 78 +/- 8 to 106 +/- 8 min.",The effect of halothane on morphine disposition: relative contributions of the liver and kidney to morphine glucuronidation in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301762/),[ml] / [min],963,193904,DB00312,Pentobarbital
,2301762,clearance (CLs),"However, intravenous (iv) morphine clearance (CLs) decreased (P less than 0.05) by 40% from 963 +/- 131 to 579 +/- 91 ml/min during halothane anesthesia, accompanied by an increase (P less than 0.05) in half-life from 78 +/- 8 to 106 +/- 8 min.",The effect of halothane on morphine disposition: relative contributions of the liver and kidney to morphine glucuronidation in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301762/),[ml] / [min],579,193905,DB00312,Pentobarbital
,2301762,half-life,"However, intravenous (iv) morphine clearance (CLs) decreased (P less than 0.05) by 40% from 963 +/- 131 to 579 +/- 91 ml/min during halothane anesthesia, accompanied by an increase (P less than 0.05) in half-life from 78 +/- 8 to 106 +/- 8 min.",The effect of halothane on morphine disposition: relative contributions of the liver and kidney to morphine glucuronidation in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301762/),min,78,193906,DB00312,Pentobarbital
,2301762,half-life,"However, intravenous (iv) morphine clearance (CLs) decreased (P less than 0.05) by 40% from 963 +/- 131 to 579 +/- 91 ml/min during halothane anesthesia, accompanied by an increase (P less than 0.05) in half-life from 78 +/- 8 to 106 +/- 8 min.",The effect of halothane on morphine disposition: relative contributions of the liver and kidney to morphine glucuronidation in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2301762/),min,106,193907,DB00312,Pentobarbital
,455607,renal venous-arterial renin ratio,This role of the kidney in renin clearance was confirmed by the finding of a renal venous-arterial renin ratio of 0.9 +/- 0.03 (P less than 0.005) during renin infusion in normal rats.,The prolonged pressor response to renin in the nephrectomized rat. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455607/),,0.9,194392,DB00312,Pentobarbital
,4057344,an,"Mean anesthesia times (to the return of the palpebral reflex) were 7.89 min (thiamylal), 5.39 min (pentobarbital) and 34.1 min (the sequential combination).",Pharmacokinetics of pentobarbital and thiamylal as combined anesthetics in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057344/),min,7.89,194512,DB00312,Pentobarbital
,4057344,an,"Mean anesthesia times (to the return of the palpebral reflex) were 7.89 min (thiamylal), 5.39 min (pentobarbital) and 34.1 min (the sequential combination).",Pharmacokinetics of pentobarbital and thiamylal as combined anesthetics in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057344/),min,5.39,194513,DB00312,Pentobarbital
,4057344,an,"Mean anesthesia times (to the return of the palpebral reflex) were 7.89 min (thiamylal), 5.39 min (pentobarbital) and 34.1 min (the sequential combination).",Pharmacokinetics of pentobarbital and thiamylal as combined anesthetics in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057344/),min,34.1,194514,DB00312,Pentobarbital
,4057344,times,"Mean anesthesia times (to the return of the palpebral reflex) were 7.89 min (thiamylal), 5.39 min (pentobarbital) and 34.1 min (the sequential combination).",Pharmacokinetics of pentobarbital and thiamylal as combined anesthetics in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057344/),min,7.89,194515,DB00312,Pentobarbital
,4057344,times,"Mean anesthesia times (to the return of the palpebral reflex) were 7.89 min (thiamylal), 5.39 min (pentobarbital) and 34.1 min (the sequential combination).",Pharmacokinetics of pentobarbital and thiamylal as combined anesthetics in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057344/),min,5.39,194516,DB00312,Pentobarbital
,4057344,times,"Mean anesthesia times (to the return of the palpebral reflex) were 7.89 min (thiamylal), 5.39 min (pentobarbital) and 34.1 min (the sequential combination).",Pharmacokinetics of pentobarbital and thiamylal as combined anesthetics in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4057344/),min,34.1,194517,DB00312,Pentobarbital
,3582175,clearance,"The mean clearance was 0.72 ml/min/kg, with a volume of distribution (Vd) of 1.03 L/kg and a terminal half-life of 19.1 h.",Pentobarbital pharmacokinetics in patients with severe head injury. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582175/),[ml] / [kg·min],0.72,201313,DB00312,Pentobarbital
,3582175,volume of distribution (Vd),"The mean clearance was 0.72 ml/min/kg, with a volume of distribution (Vd) of 1.03 L/kg and a terminal half-life of 19.1 h.",Pentobarbital pharmacokinetics in patients with severe head injury. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582175/),[l] / [kg],1.03,201314,DB00312,Pentobarbital
,3582175,terminal half-life,"The mean clearance was 0.72 ml/min/kg, with a volume of distribution (Vd) of 1.03 L/kg and a terminal half-life of 19.1 h.",Pentobarbital pharmacokinetics in patients with severe head injury. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3582175/),h,19.1,201315,DB00312,Pentobarbital
,29162023,clearance,"While on CVVH, the patient's estimated pentobarbital clearance ranged from 6 to 44 mL/min and the elimination half-life ranged from 17.7 to 65.9 hours.",Pentobarbital Removal During Continuous Venovenous Hemofiltration: Case Report and Review of the Literature. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162023/),[ml] / [min],6 to 44,202197,DB00312,Pentobarbital
,29162023,elimination half-life,"While on CVVH, the patient's estimated pentobarbital clearance ranged from 6 to 44 mL/min and the elimination half-life ranged from 17.7 to 65.9 hours.",Pentobarbital Removal During Continuous Venovenous Hemofiltration: Case Report and Review of the Literature. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29162023/),h,17.7 to 65.9,202198,DB00312,Pentobarbital
,2893696,Biliary excretion,Biliary excretion of radioactivity averaged 54.3 +/- 18.0% of the dose over a 7.5-8-hr period in pentobarbital-anesthesized rats.,The disposition and pharmacokinetics of ketoconazole in the rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),%,54.3,202272,DB00312,Pentobarbital
,2893696,VD,"In eight male rats, the plasma pharmacokinetics of ketoconazole, as determined by an HPLC assay with fluorescence detection, were as follows: VD = 655 +/- 91 ml/kg, Cl = 14.4 +/- 5.1 ml/min/kg, and t 1/2 = 35.0 +/- 12.3 min.",The disposition and pharmacokinetics of ketoconazole in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),[ml] / [kg],655,202273,DB00312,Pentobarbital
,2893696,Cl,"In eight male rats, the plasma pharmacokinetics of ketoconazole, as determined by an HPLC assay with fluorescence detection, were as follows: VD = 655 +/- 91 ml/kg, Cl = 14.4 +/- 5.1 ml/min/kg, and t 1/2 = 35.0 +/- 12.3 min.",The disposition and pharmacokinetics of ketoconazole in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),[ml] / [kg·min],14.4,202274,DB00312,Pentobarbital
,2893696,t 1/2,"In eight male rats, the plasma pharmacokinetics of ketoconazole, as determined by an HPLC assay with fluorescence detection, were as follows: VD = 655 +/- 91 ml/kg, Cl = 14.4 +/- 5.1 ml/min/kg, and t 1/2 = 35.0 +/- 12.3 min.",The disposition and pharmacokinetics of ketoconazole in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),min,35.0,202275,DB00312,Pentobarbital
,2893696,time to peak,"The time to peak was 30-60 min, and the bioavailability was 35.8 +/- 3.55%.",The disposition and pharmacokinetics of ketoconazole in the rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),min,30-60,202276,DB00312,Pentobarbital
,2893696,bioavailability,"The time to peak was 30-60 min, and the bioavailability was 35.8 +/- 3.55%.",The disposition and pharmacokinetics of ketoconazole in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2893696/),%,35.8,202277,DB00312,Pentobarbital
<,7625572,half-life,Fitting of the experimental data to a two-compartmental mammillary model revealed that the labeled compounds are eliminated from the plasma with a half-life of < 1 min during the early time following the intravenous injection and that a large portion of the EthLin is hydrolyzed instantly to linoleic acid and ethanol.,Turnover of ethyl-linoleate in rat plasma and its distribution in various organs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7625572/),min,1,203401,DB00312,Pentobarbital
,10598612,steady state clearance (Clss),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),[l] / [min],0.108,208009,DB00312,Pentobarbital
,10598612,steady state clearance (Clss),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),[l] / [min],0.096,208010,DB00312,Pentobarbital
,10598612,volume of distribution (Vd),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),l,313,208011,DB00312,Pentobarbital
,10598612,volume of distribution (Vd),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),l,273,208012,DB00312,Pentobarbital
,10598612,maximal rate of metabolism (Vm),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),[mg] / [h·l],1.01,208013,DB00312,Pentobarbital
,10598612,maximal rate of metabolism (Vm),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),[mg] / [h·l],0.86,208014,DB00312,Pentobarbital
,10598612,elimination half-lives,"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),h,14.6,208015,DB00312,Pentobarbital
,10598612,elimination half-lives,"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),h,14.7,208016,DB00312,Pentobarbital
,10598612,unbound fractions (f(u)),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),,0.20,208017,DB00312,Pentobarbital
,10598612,unbound fractions (f(u)),"Paired analysis indicated that steady state clearance (Clss) and volume of distribution (Vd) were higher for R-thiopental (0.108 vs. 0.096 l/min, P < 0.0001; and 313 vs. 273 l, P < 0.0005, respectively); maximal rate of metabolism (Vm) was higher for S- than for R-thiopental (1.01 vs. 0.86 mg x l(-1) x h(-1), P = 0.02); elimination half-lives did not differ (14.6 vs. 14.7 h, P = 0.8); unbound fractions (f(u)) of R- and S-thiopental were 0.20 and 0.18, respectively, P < 0.0001).",Pharmacokinetics of thiopental enantiomers during and following prolonged high-dose therapy. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598612/),,0.18,208018,DB00312,Pentobarbital
,2571473,mean residence time (MRT),"Following a single iv dose of 40 mg/kg sodium pentobarbital, the average mean residence time (MRT) was prolonged by 144% (2.3 +/- 0.2 to 5.6 +/- 1.5 hr, mean +/- SD) in the protein-deficient rats, whereas the mean total body clearance (CL) per kilogram of body weight decreased from 0.56 +/- 0.09 to 0.22 +/- 0.06 liter/hr/kg.",Influence of nutritional status on the pharmacokinetics and pharmacodynamics of pentobarbital. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571473/),h,2.3,212100,DB00312,Pentobarbital
,2571473,mean residence time (MRT),"Following a single iv dose of 40 mg/kg sodium pentobarbital, the average mean residence time (MRT) was prolonged by 144% (2.3 +/- 0.2 to 5.6 +/- 1.5 hr, mean +/- SD) in the protein-deficient rats, whereas the mean total body clearance (CL) per kilogram of body weight decreased from 0.56 +/- 0.09 to 0.22 +/- 0.06 liter/hr/kg.",Influence of nutritional status on the pharmacokinetics and pharmacodynamics of pentobarbital. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571473/),h,5.6,212101,DB00312,Pentobarbital
,2571473,total body clearance (CL),"Following a single iv dose of 40 mg/kg sodium pentobarbital, the average mean residence time (MRT) was prolonged by 144% (2.3 +/- 0.2 to 5.6 +/- 1.5 hr, mean +/- SD) in the protein-deficient rats, whereas the mean total body clearance (CL) per kilogram of body weight decreased from 0.56 +/- 0.09 to 0.22 +/- 0.06 liter/hr/kg.",Influence of nutritional status on the pharmacokinetics and pharmacodynamics of pentobarbital. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571473/),[l] / [h·kg],0.56,212102,DB00312,Pentobarbital
,2571473,total body clearance (CL),"Following a single iv dose of 40 mg/kg sodium pentobarbital, the average mean residence time (MRT) was prolonged by 144% (2.3 +/- 0.2 to 5.6 +/- 1.5 hr, mean +/- SD) in the protein-deficient rats, whereas the mean total body clearance (CL) per kilogram of body weight decreased from 0.56 +/- 0.09 to 0.22 +/- 0.06 liter/hr/kg.",Influence of nutritional status on the pharmacokinetics and pharmacodynamics of pentobarbital. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571473/),[l] / [h·kg],0.22,212103,DB00312,Pentobarbital
,2571473,terminal disposition rate constant,"As a result, the terminal disposition rate constant was decreased by approximately 60% (0.398 +/- 0.037 to 0.178 +/- 0.050 hr-1 when compared to rats on a normal protein diet.",Influence of nutritional status on the pharmacokinetics and pharmacodynamics of pentobarbital. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571473/),1/[h],0.398,212104,DB00312,Pentobarbital
,2571473,terminal disposition rate constant,"As a result, the terminal disposition rate constant was decreased by approximately 60% (0.398 +/- 0.037 to 0.178 +/- 0.050 hr-1 when compared to rats on a normal protein diet.",Influence of nutritional status on the pharmacokinetics and pharmacodynamics of pentobarbital. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571473/),1/[h],0.178,212105,DB00312,Pentobarbital
,3598902,clearance,"Thus, the median clearance of the S-enantiomer (1.96 liters/h) was 25% less than that of the R-isomer (2.58 liters/h).",Pharmacokinetics of pentobarbital enantiomers as determined by enantioselective radioimmunoassay after administration of racemate to humans and rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598902/),[l] / [h],1.96,213259,DB00312,Pentobarbital
,3598902,clearance,"Thus, the median clearance of the S-enantiomer (1.96 liters/h) was 25% less than that of the R-isomer (2.58 liters/h).",Pharmacokinetics of pentobarbital enantiomers as determined by enantioselective radioimmunoassay after administration of racemate to humans and rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598902/),[l] / [h],2.58,213260,DB00312,Pentobarbital
up to,11304943,t1/2,From the results macromolecules with sizes ranging between 30-300 kDa were characterized by excessive liver (21%-57% retained activity) and kidney (40% retained activity) uptake and accompanying long residing times (t1/2 up to 24 h).,Biodistribution and pharmacokinetics of variously sized molecular radiolabelled polyethyleneiminomethyl phosphonic acid as a selective bone seeker for therapy in the normal primate model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304943/),h,24,217186,DB00312,Pentobarbital
,11304943,percentage bone uptake,The percentage bone uptake averaged at 8% for these particles excluding sizes 100-300 kDa where very little bone uptake was seen (< 1%).,Biodistribution and pharmacokinetics of variously sized molecular radiolabelled polyethyleneiminomethyl phosphonic acid as a selective bone seeker for therapy in the normal primate model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304943/),%,8,217187,DB00312,Pentobarbital
,11304943,t1/2,In this case the blood clearance was also slow (t1/2 approximately 2 h).,Biodistribution and pharmacokinetics of variously sized molecular radiolabelled polyethyleneiminomethyl phosphonic acid as a selective bone seeker for therapy in the normal primate model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304943/),h,2,217188,DB00312,Pentobarbital
,11304943,t1/2,"The fraction size 10-30 kDa had comparatively low accumulation and short residence times in the liver and kidneys (resp. 20%, t1/2 = 22 +/- 4 min; 17.5%, t1/2 = 20 +/- 3 min) and although the bone uptake of 18% in this case was high, it is still low for a bone-seeking agent.",Biodistribution and pharmacokinetics of variously sized molecular radiolabelled polyethyleneiminomethyl phosphonic acid as a selective bone seeker for therapy in the normal primate model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304943/),min,22,217189,DB00312,Pentobarbital
,11304943,t1/2,"The fraction size 10-30 kDa had comparatively low accumulation and short residence times in the liver and kidneys (resp. 20%, t1/2 = 22 +/- 4 min; 17.5%, t1/2 = 20 +/- 3 min) and although the bone uptake of 18% in this case was high, it is still low for a bone-seeking agent.",Biodistribution and pharmacokinetics of variously sized molecular radiolabelled polyethyleneiminomethyl phosphonic acid as a selective bone seeker for therapy in the normal primate model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304943/),min,20,217190,DB00312,Pentobarbital
,11304943,bone uptake,"The fraction size 10-30 kDa had comparatively low accumulation and short residence times in the liver and kidneys (resp. 20%, t1/2 = 22 +/- 4 min; 17.5%, t1/2 = 20 +/- 3 min) and although the bone uptake of 18% in this case was high, it is still low for a bone-seeking agent.",Biodistribution and pharmacokinetics of variously sized molecular radiolabelled polyethyleneiminomethyl phosphonic acid as a selective bone seeker for therapy in the normal primate model. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304943/),%,18,217191,DB00312,Pentobarbital
,11304943,t1/2,These particles cleared the blood with t1/2 = 25 +/- 2 min and seemed suitable for labelling with a therapeutic radioisotopic agent.,Biodistribution and pharmacokinetics of variously sized molecular radiolabelled polyethyleneiminomethyl phosphonic acid as a selective bone seeker for therapy in the normal primate model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304943/),min,25,217192,DB00312,Pentobarbital
,1282046,half-life,"Spectrophotometric analysis of rat serum showed rapid elimination of MB from the vascular system, with a half-life of 3.5 +/- 1.9 minutes.","Limitations of monastral blue as a vascular label: rapid rate of clearance is age-dependent, and interactions with anesthetics depress arterial blood pressure in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1282046/),min,3.5,225221,DB00312,Pentobarbital
,9423145,bioavailability,"Nasal bioavailability in dogs anesthetized with pentobarbital was 85 +/- 4%, whereas in dogs anesthetized with the short-acting anesthetic propofol, bioavailability was 32 +/- 7%.","Intranasal absorption of the platelet glycoprotein IIb/IIIa receptor antagonist, DMP 755, and the effect of anesthesia on nasal bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423145/),%,85,231915,DB00312,Pentobarbital
,9423145,bioavailability,"Nasal bioavailability in dogs anesthetized with pentobarbital was 85 +/- 4%, whereas in dogs anesthetized with the short-acting anesthetic propofol, bioavailability was 32 +/- 7%.","Intranasal absorption of the platelet glycoprotein IIb/IIIa receptor antagonist, DMP 755, and the effect of anesthesia on nasal bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423145/),%,32,231916,DB00312,Pentobarbital
,21665222,CL,"A typical infant (two-ventricle physiology, 6.9 kg, 5.2 months, and bypass grafting time of 60 minutes) had a CL of 0.12 L/hr/kg, V1 of 0.45 L/kg, and peripheral volume of distributions of 0.98 L/kg.","Population pharmacokinetics of pentobarbital in neonates, infants, and children after open heart surgery. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665222/),[l] / [h·kg],0.12,232930,DB00312,Pentobarbital
,21665222,V1,"A typical infant (two-ventricle physiology, 6.9 kg, 5.2 months, and bypass grafting time of 60 minutes) had a CL of 0.12 L/hr/kg, V1 of 0.45 L/kg, and peripheral volume of distributions of 0.98 L/kg.","Population pharmacokinetics of pentobarbital in neonates, infants, and children after open heart surgery. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665222/),[l] / [kg],0.45,232931,DB00312,Pentobarbital
,21665222,peripheral volume of distributions,"A typical infant (two-ventricle physiology, 6.9 kg, 5.2 months, and bypass grafting time of 60 minutes) had a CL of 0.12 L/hr/kg, V1 of 0.45 L/kg, and peripheral volume of distributions of 0.98 L/kg.","Population pharmacokinetics of pentobarbital in neonates, infants, and children after open heart surgery. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665222/),[l] / [kg],0.98,232932,DB00312,Pentobarbital
,2764164,Vmax,"Vmax was 1) accurately determined using two, three, or four doses of ICG; 2) it was 1.09 +/- 0.16 mg.kg-1.min-1, not different from the Vo of the near-saturating dose of 25 mg/kg; and 3) it decreased after partial hepatectomy.","Measurement of hepatocellular function, cardiac output, effective blood volume, and oxygen saturation in rats. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764164/),[mg] / [kg·min],1.09,234658,DB00312,Pentobarbital
,2764164,Cardiac output,"Cardiac output was 41.89 +/- 1.46 ml.100 g-1.min-1, effective blood volume was 6.12 +/- 0.34 ml/100 g, and oxygen saturation was 92 +/- 2%.","Measurement of hepatocellular function, cardiac output, effective blood volume, and oxygen saturation in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764164/),[100·ml] / [g·min],41.89,234659,DB00312,Pentobarbital
,2764164,effective blood volume,"Cardiac output was 41.89 +/- 1.46 ml.100 g-1.min-1, effective blood volume was 6.12 +/- 0.34 ml/100 g, and oxygen saturation was 92 +/- 2%.","Measurement of hepatocellular function, cardiac output, effective blood volume, and oxygen saturation in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764164/),[ml] / [100·g],6.12,234660,DB00312,Pentobarbital
,2764164,oxygen saturation,"Cardiac output was 41.89 +/- 1.46 ml.100 g-1.min-1, effective blood volume was 6.12 +/- 0.34 ml/100 g, and oxygen saturation was 92 +/- 2%.","Measurement of hepatocellular function, cardiac output, effective blood volume, and oxygen saturation in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2764164/),%,92,234661,DB00312,Pentobarbital
,25330755,elimination rate constant,The median calculated elimination rate constant [0.155 (0.108-0.17) vs. 0.103 (0.08-0.142) hr(-1); p = 0.04] was significantly higher than the predicted value.,"Vancomycin pharmacokinetic parameters in patients with acute brain injury undergoing controlled normothermia, therapeutic hypothermia, or pentobarbital infusion. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25330755/),1/[hr],0.155,243116,DB00312,Pentobarbital
,25330755,elimination rate constant,The median calculated elimination rate constant [0.155 (0.108-0.17) vs. 0.103 (0.08-0.142) hr(-1); p = 0.04] was significantly higher than the predicted value.,"Vancomycin pharmacokinetic parameters in patients with acute brain injury undergoing controlled normothermia, therapeutic hypothermia, or pentobarbital infusion. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25330755/),1/[hr],0.103,243117,DB00312,Pentobarbital
,25330755,trough concentration,The median measured trough concentration [8.9 (7.7-11.1) vs. 17.1 (10.8-22.3) υg/mL; p = 0.004] was significantly lower than predicted.,"Vancomycin pharmacokinetic parameters in patients with acute brain injury undergoing controlled normothermia, therapeutic hypothermia, or pentobarbital infusion. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25330755/),[υg] / [ml],8.9,243118,DB00312,Pentobarbital
,25330755,trough concentration,The median measured trough concentration [8.9 (7.7-11.1) vs. 17.1 (10.8-22.3) υg/mL; p = 0.004] was significantly lower than predicted.,"Vancomycin pharmacokinetic parameters in patients with acute brain injury undergoing controlled normothermia, therapeutic hypothermia, or pentobarbital infusion. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25330755/),[υg] / [ml],17.1,243119,DB00312,Pentobarbital
,25330755,elimination rate constant,No significant differences were found between the median calculated and predicted elimination rate constant [0.107 (0.097-0.109) vs. 0.112 (0.102-0.127) hr(-1); p = 0.41] and median measured and predicted trough concentration [14.2 (12.7-17.1) vs. 13.1 (11-17.8) υg/mL; p = 0.71].,"Vancomycin pharmacokinetic parameters in patients with acute brain injury undergoing controlled normothermia, therapeutic hypothermia, or pentobarbital infusion. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25330755/),1/[hr],0.107,243120,DB00312,Pentobarbital
,25330755,elimination rate constant,No significant differences were found between the median calculated and predicted elimination rate constant [0.107 (0.097-0.109) vs. 0.112 (0.102-0.127) hr(-1); p = 0.41] and median measured and predicted trough concentration [14.2 (12.7-17.1) vs. 13.1 (11-17.8) υg/mL; p = 0.71].,"Vancomycin pharmacokinetic parameters in patients with acute brain injury undergoing controlled normothermia, therapeutic hypothermia, or pentobarbital infusion. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25330755/),1/[hr],0.112,243121,DB00312,Pentobarbital
,25330755,trough concentration,No significant differences were found between the median calculated and predicted elimination rate constant [0.107 (0.097-0.109) vs. 0.112 (0.102-0.127) hr(-1); p = 0.41] and median measured and predicted trough concentration [14.2 (12.7-17.1) vs. 13.1 (11-17.8) υg/mL; p = 0.71].,"Vancomycin pharmacokinetic parameters in patients with acute brain injury undergoing controlled normothermia, therapeutic hypothermia, or pentobarbital infusion. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25330755/),[υg] / [ml],14.2,243122,DB00312,Pentobarbital
,25330755,trough concentration,No significant differences were found between the median calculated and predicted elimination rate constant [0.107 (0.097-0.109) vs. 0.112 (0.102-0.127) hr(-1); p = 0.41] and median measured and predicted trough concentration [14.2 (12.7-17.1) vs. 13.1 (11-17.8) υg/mL; p = 0.71].,"Vancomycin pharmacokinetic parameters in patients with acute brain injury undergoing controlled normothermia, therapeutic hypothermia, or pentobarbital infusion. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25330755/),[υg] / [ml],13.1,243123,DB00312,Pentobarbital
,3385601,brain to plasma concentration ratio,The brain to plasma concentration ratio of pentobarbital was 1.5 and was almost constant during the experiment.,Effect of chlorpromazine on the pharmacokinetics and pharmacodynamics of pentobarbital in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385601/),,1.5,245163,DB00312,Pentobarbital
,3385601,hepatic intrinsic clearance,The hepatic intrinsic clearance of pentobarbital was decreased from 0.438 to 0.331 l/h by chlorpromazine coadministration.,Effect of chlorpromazine on the pharmacokinetics and pharmacodynamics of pentobarbital in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385601/),[l] / [h],0.438,245164,DB00312,Pentobarbital
,3385601,hepatic intrinsic clearance,The hepatic intrinsic clearance of pentobarbital was decreased from 0.438 to 0.331 l/h by chlorpromazine coadministration.,Effect of chlorpromazine on the pharmacokinetics and pharmacodynamics of pentobarbital in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3385601/),[l] / [h],0.331,245165,DB00312,Pentobarbital
,891094,plasma half-life,"Antipyrine plasma half-life increased during THC in 5 of 6 subjects--mean, 7.9 hr +/- 3.3 (SD) to 9.6 +/- 3.8.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,7.9,246096,DB00312,Pentobarbital
,891094,plasma half-life,"Antipyrine plasma half-life increased during THC in 5 of 6 subjects--mean, 7.9 hr +/- 3.3 (SD) to 9.6 +/- 3.8.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,9.6,246097,DB00312,Pentobarbital
,891094,half-life,"Pentobarbital half-life increased in 7 of 8 subjects--mean, 16.9 hr +/- 2.0 to 20.8 +/- 4.2.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,16.9,246098,DB00312,Pentobarbital
,891094,half-life,"Pentobarbital half-life increased in 7 of 8 subjects--mean, 16.9 hr +/- 2.0 to 20.8 +/- 4.2.","Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),h,20.8,246099,DB00312,Pentobarbital
,891094,Blood ethanol disappearance rate,Blood ethanol disappearance rate decreased in 7 of 8 subjects from a mean of 0.26 mg/100 ml/min +/- 0.05 to 0.23 +/- 0.07.,"Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),[mg] / [100·min·ml],0.26,246100,DB00312,Pentobarbital
,891094,Blood ethanol disappearance rate,Blood ethanol disappearance rate decreased in 7 of 8 subjects from a mean of 0.26 mg/100 ml/min +/- 0.05 to 0.23 +/- 0.07.,"Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. ",km-Q51,[Article Link](https://pubmed.ncbi.nlm.nih.gov/891094/),[mg] / [100·min·ml],0.23,246101,DB00312,Pentobarbital
,8611958,flow-rate,The mobile phase was 4.5% 2-propanol in 0.1 M phosphate buffer (pH 6.2) with a flow-rate of 0.9 ml/min.,High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),[ml] / [min],0.9,252593,DB00312,Pentobarbital
,8611958,k',"This gave k' values of 1.92, 2.92, 5.71, 9.30 and 11.98 for R(+)-pentobarbitone, S(-)-pentobarbitone, R(+)-thiopentone, S(-)-thiopentone, and phenylbutazone, respectively.",High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),,1.92,252594,DB00312,Pentobarbital
,8611958,k',"This gave k' values of 1.92, 2.92, 5.71, 9.30 and 11.98 for R(+)-pentobarbitone, S(-)-pentobarbitone, R(+)-thiopentone, S(-)-thiopentone, and phenylbutazone, respectively.",High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),,2.92,252595,DB00312,Pentobarbital
,8611958,k',"This gave k' values of 1.92, 2.92, 5.71, 9.30 and 11.98 for R(+)-pentobarbitone, S(-)-pentobarbitone, R(+)-thiopentone, S(-)-thiopentone, and phenylbutazone, respectively.",High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),,5.71,252596,DB00312,Pentobarbital
,8611958,k',"This gave k' values of 1.92, 2.92, 5.71, 9.30 and 11.98 for R(+)-pentobarbitone, S(-)-pentobarbitone, R(+)-thiopentone, S(-)-thiopentone, and phenylbutazone, respectively.",High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),,9.30,252597,DB00312,Pentobarbital
,8611958,k',"This gave k' values of 1.92, 2.92, 5.71, 9.30 and 11.98 for R(+)-pentobarbitone, S(-)-pentobarbitone, R(+)-thiopentone, S(-)-thiopentone, and phenylbutazone, respectively.",High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),,11.98,252598,DB00312,Pentobarbital
,4024211,CLT,"Preinduction and induction CLT were 4.22 and 8.02 L/h, respectively, which represented a 95% increase in the CLT as a consequence of pentobarbital therapy.",Influence of high-dose pentobarbital on theophylline pharmacokinetics: a case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024211/),[l] / [h],4.22,254110,DB00312,Pentobarbital
,4024211,CLT,"Preinduction and induction CLT were 4.22 and 8.02 L/h, respectively, which represented a 95% increase in the CLT as a consequence of pentobarbital therapy.",Influence of high-dose pentobarbital on theophylline pharmacokinetics: a case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4024211/),[l] / [h],8.02,254111,DB00312,Pentobarbital
,7931891,clearance,"Vincristine clearance, estimated by Bayesian methods, was highly variable, with a mean (SD) clearance of 19.9 (14.9) ml/min per kilogram or 482 (342) ml/min per square meter.",Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931891/),[ml] / [kg·min],19.9,259481,DB00312,Pentobarbital
,7931891,clearance,"Vincristine clearance, estimated by Bayesian methods, was highly variable, with a mean (SD) clearance of 19.9 (14.9) ml/min per kilogram or 482 (342) ml/min per square meter.",Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931891/),[ml] / [meter·min·square],482,259482,DB00312,Pentobarbital
,517820,half-life,The mean half-life of the drug in adult dogs injected IV was 4.5 hours.,Relationship between serum and brain concentrations of phenytoin in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/517820/),h,4.5,262555,DB00312,Pentobarbital
below,25700623,peak TA concentration,"Following a 50μL suprachoroidal injection, peak TA concentration in the aqueous was below 1ng/mL.",Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700623/),[ng] / [ml],1,264144,DB00312,Pentobarbital
,25700623,Maximum TA,Maximum TA in plasma was 11.6ng/mL.,Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700623/),[ng] / [ml],11.6,264145,DB00312,Pentobarbital
,2924373,terminal half-lives,"Plasma concentrations of both drugs declined biexponentially, with terminal half-lives of 90.6 min for MTX and 97.2 min for 7-OH-MTX.",Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924373/),min,90.6,264376,DB00312,Pentobarbital
,2924373,terminal half-lives,"Plasma concentrations of both drugs declined biexponentially, with terminal half-lives of 90.6 min for MTX and 97.2 min for 7-OH-MTX.",Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924373/),min,97.2,264377,DB00312,Pentobarbital
,2924373,total clearance,"The total clearance values were 9.2 and 9.6 ml x kg-1 x min-1, respectively.",Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924373/),[ml] / [kg·min],9.2,264378,DB00312,Pentobarbital
,2924373,total clearance,"The total clearance values were 9.2 and 9.6 ml x kg-1 x min-1, respectively.",Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924373/),[ml] / [kg·min],9.6,264379,DB00312,Pentobarbital
,23182722,retention time,Pharmacokinetics of SK-20 revealed it to have retention time at 10.2 min and half life 2.47 h.,"Acute, sub-acute and general pharmacological evaluation of 5-(3,4-methylenedioxyphenyl)-4-ethyl-2E,4E-pentadienoic acid piperidide (SK-20): a novel drug bioavailability enhancer. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23182722/),min,10.2,266807,DB00312,Pentobarbital
,23182722,half life,Pharmacokinetics of SK-20 revealed it to have retention time at 10.2 min and half life 2.47 h.,"Acute, sub-acute and general pharmacological evaluation of 5-(3,4-methylenedioxyphenyl)-4-ethyl-2E,4E-pentadienoic acid piperidide (SK-20): a novel drug bioavailability enhancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23182722/),h,2.47,266808,DB00312,Pentobarbital
,4042529,t1/2,"On discontinuation of the pentobarbital infusion, serum concentrations in the patients followed a monoexponential decline with a mean (+/- SD) t1/2 and Vss that were significantly less than values reported for the control subjects (15.6 +/- 3.9 vs. 22.3 +/- 4.0 hours and 44.0 +/- 11.7 vs. 63.4 +/- 15.2 L, respectively).",Pharmacokinetics of high-dose pentobarbital in severe head trauma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042529/),h,15.6,272163,DB00312,Pentobarbital
,4042529,Vss,"On discontinuation of the pentobarbital infusion, serum concentrations in the patients followed a monoexponential decline with a mean (+/- SD) t1/2 and Vss that were significantly less than values reported for the control subjects (15.6 +/- 3.9 vs. 22.3 +/- 4.0 hours and 44.0 +/- 11.7 vs. 63.4 +/- 15.2 L, respectively).",Pharmacokinetics of high-dose pentobarbital in severe head trauma. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042529/),h,22.3,272164,DB00312,Pentobarbital
,4042529,Vss,"On discontinuation of the pentobarbital infusion, serum concentrations in the patients followed a monoexponential decline with a mean (+/- SD) t1/2 and Vss that were significantly less than values reported for the control subjects (15.6 +/- 3.9 vs. 22.3 +/- 4.0 hours and 44.0 +/- 11.7 vs. 63.4 +/- 15.2 L, respectively).",Pharmacokinetics of high-dose pentobarbital in severe head trauma. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042529/),l,44.0,272165,DB00312,Pentobarbital
,4042529,Vss,"On discontinuation of the pentobarbital infusion, serum concentrations in the patients followed a monoexponential decline with a mean (+/- SD) t1/2 and Vss that were significantly less than values reported for the control subjects (15.6 +/- 3.9 vs. 22.3 +/- 4.0 hours and 44.0 +/- 11.7 vs. 63.4 +/- 15.2 L, respectively).",Pharmacokinetics of high-dose pentobarbital in severe head trauma. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042529/),l,63.4,272166,DB00312,Pentobarbital
,4042529,CL,"However, there was no significant difference between the mean pentobarbital CL of the patients (2.0 +/- 0.7 L/hr) and the subjects (2.0 +/- 0.4 L/hr).",Pharmacokinetics of high-dose pentobarbital in severe head trauma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042529/),[l] / [h],2.0,272167,DB00312,Pentobarbital
,4042529,CL,"However, there was no significant difference between the mean pentobarbital CL of the patients (2.0 +/- 0.7 L/hr) and the subjects (2.0 +/- 0.4 L/hr).",Pharmacokinetics of high-dose pentobarbital in severe head trauma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042529/),[l] / [h],2.0,272168,DB00312,Pentobarbital
,7631771,times,"The times required for the subcutaneously implanted sensor to reach its maximum current, corrected for sensor response times, were 7.5 +/- 3.9, 9.8 +/- 5.5, and 10.0 +/- 4.4 min for the smallest to the largest dose, respectively.",Kinetics of glucose delivery to subcutaneous tissue in rats measured with 0.3-mm amperometric microsensors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631771/),min,7.5,273421,DB00312,Pentobarbital
,7631771,times,"The times required for the subcutaneously implanted sensor to reach its maximum current, corrected for sensor response times, were 7.5 +/- 3.9, 9.8 +/- 5.5, and 10.0 +/- 4.4 min for the smallest to the largest dose, respectively.",Kinetics of glucose delivery to subcutaneous tissue in rats measured with 0.3-mm amperometric microsensors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631771/),min,9.8,273422,DB00312,Pentobarbital
,7631771,times,"The times required for the subcutaneously implanted sensor to reach its maximum current, corrected for sensor response times, were 7.5 +/- 3.9, 9.8 +/- 5.5, and 10.0 +/- 4.4 min for the smallest to the largest dose, respectively.",Kinetics of glucose delivery to subcutaneous tissue in rats measured with 0.3-mm amperometric microsensors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7631771/),min,10.0,273423,DB00312,Pentobarbital
